СПОСОБ ХРАНЕНИЯ ЭРИТРОЦИТОВ В УСЛОВИЯХ ОХЛАЖДЕНИЯ ПРИ ОТСУТСТВИИ КИСЛОРОДА (ВАРИАНТЫ)

Способ хранения эритроцитов включает стадии смешивания образца цельной крови, содержащей эритроциты, с антикоагулянтным раствором с формированием таким образом первой суспензии эритроцитов, концентрирования эритроцитов из жидкой части первой суспензии с получением массы уплотненных эритроцитов, смешивания уплотненных эритроцитов с консервирующим раствором, который включает глюкозу, аденин и соли, с формированием таким образом второй суспензии эритроцитов, снижения уровня кислорода эритроцитов во второй суспензии эритроцитов до примерно 8% от их уровня насыщения или ниже путем промывания эритроцитов инертным газом и охлаждения второй суспензии эритроцитов до 4oС. Технический результат: способ обеспечивает сохранность качества эритроцитов и продлевает их выживаемость in vivo после переливания крови. 2 с. и 12 з.п. ф-лы, 4 ил.

ОБРАБОТКА ОРГАНОВ EX VIVO МОЛЕКУЛАМИ ПЭГ-ФОСФОЛИПИДА

Изобретение относится к области биотехнологии. Описан способ ex vivo обеспечения покрытия по меньшей мере части эндотелиальной выстилки сосудистой системы органа или части органа. Способ включает стадии инфузии ex vivo раствора, содержащего молекулы ПЭГ-фосфолипида, в сосудистую систему органа или части органа; и инкубации ex vivo раствора, содержащего молекулы ПЭГ-фосфолипида, в сосудистой системе. Способ позволяет формировать защиту от тромбовоспаления, вызванного перфузией органа или части органа. 14 з.п. ф-лы, 58 ил., 4 пр.

СПОСОБ ПОЛУЧЕНИЯ ДЕЗИНФИЦИРОВАННЫХ СУСПЕНЗИЙ КЛЕТОК ЧЕЛОВЕКА

Изобретение относится к биотехнологии. Предложен способ получения дезинфицированного препарата клеток из ткани млекопитающего. Осуществляют перфузию ткани млекопитающего не содержащим фермент жидким составом антибиотика, содержащим по меньшей мере один антибиотик и буферный раствор для перфузии. По окончании предыдущей стадии обрабатывают ткань ферментами без антибиотиков для получения суспензии отдельных клеток. Получают дезинфицированный препарат клеток. Изобретение позволяет за короткое время достичь высокого выхода клеток, а также высокой жизнеспособности изолированных дезинфицированных клеток с содержанием микроорганизмов менее 10КОЕ в единице дезинфицированного препарата. 6 з.п. ф-лы, 2 пр.

Среда для разбавления спермы сельскохозяйственной птицы

Изобретение относится к сельскому хозяйству, а именно к средам для искусственного осеменения сельскохозяйственной птицы. Среда для разбавления спермы птицы изготовлена путем растворения в 100 мл бидистиллированной воды сухих компонентов, взятых при следующем соотношении (г): сахароза - 4,0-5,0, глюкоза - 0,3-0,5, уксуснокислый натрий - 1,1-1,6, углекислый кислый натрий - 0,1-0,2, щавелевая кислота - 0,02-0,04, при этом среда обеспечивает время хранения разбавленной спермы при сохранении оплодотворяющей способности для кур 24 часа, цесарок и индеек - 7 часов, уток - 4 часа, гусей - 3 часа. Предлагаемая среда эффективна при разбавлении спермы для искусственного осеменения кур, индеек, цесарок, гусей, уток, в сухом виде среда может храниться без доступа воздуха до 2-х месяцев при температуре +6-8°C без изменения первоначальных свойств. 3 табл.

ПРИГОТОВЛЕНИЕ ПРИГОДНОЙ ДЛЯ ХРАНЕНИЯ СУСПЕНЗИИ ЖИЗНЕСПОСОБНЫХ ЯИЦ ГЛИСТОВ

Изобретение относится к фармацевтической промышленности, а именно к способу приготовления фармацевтического препарата для лечения воспалительных заболеваний кишечного тракта. Способ приготовления фармацевтического препарата для перорального применения для лечения воспалительных заболеваний кишечного тракта, прежде всего хронических воспалительных заболеваний кишечного тракта, содержащего пригодную для хранения суспензию жизнеспособных яиц паразитических, не патогенных для человека гельминтов Trichuris suis, который включает обработку суспензии яиц гельминтов кислотой при значении рН не более 2 на первой стадии, а на другой стадии значение рН повышают до уровня не менее 4 и добавляют фармакологически приемлемый консервант. Фармацевтический препарат для перорального применения для лечения воспалительных заболеваний кишечного тракта, прежде всего хронических воспалительных заболеваний кишечного тракта. Применение фармацевтического препарата для перорального применения для лечения воспалительных ...

СПОСОБ ВИТРИФИКАЦИИ ОВАРИАЛЬНОЙ ТКАНИ

Изобретение относится к области медицины, а именно к онкогинекологии и репродуктивной медицине, и предназначено для сохранения репродуктивной функции женщин с онкологическими заболеваниями, желающих в дальнейшем иметь детей. Способ витрификации овариальной ткани включает подготовку образцов овариальной ткани, их двухэтапное насыщение криопротекторами в среде, содержащей 7,5% раствор ДМСО и 7,5% ЭГ, 0,5 М сахарозы, причем фрагменты ткани хранят в стерильных криопробирках с жидким азотом. Подготовку образцов ткани яичника для витрификации проводят путем удаления кортикального слоя от мозгового слоя яичника. Толщину кортикального слоя задают не более 1 мм и делят на фрагменты по 2-5 мм × 2-5 мм при +4С. Затем фрагменты ткани насыщают растворами криопротекторов в два этапа. На первом этапе фрагменты ткани пропитывают в течение до 20 мин в среде для витрификации, содержащей неорганические соли - 10,5 г/л, аминокислоты - 1,0 г/л, витамины - 0,10 г/л, глюкозу - 1,0 г/л, пенициллин-стрептомицин ...

ВОДНЫЙ РАСТВОР ДЛЯ КОНСЕРВАЦИИ ТКАНЕЙ И ОРГАНОВ

Изобретение относится к медицине. Водный раствор для консервации тканей и органов включает эффективное количество карведилола, эффективное количество такролимуса и эффективное количество триметазидина. Ткани и органы хранят в растворе при температуре 2-10°С. Изобретение позволяет повысить степень защиты органов и тканей. 3 н. и 10 з.п. ф-лы, 10 ил., 6 табл.

Добавочный раствор для хранения отмытых размороженных эритроцитов

Изобретение относится к медицине, а именно к растворам для ресуспендирования и хранения компонентов заготовленной донорской крови и, в частности, для ресуспендирования и хранения размороженных после криоконсервирования, отмытых от криоконсерванта эритроцитов. Добавочный раствор для хранения отмытых размороженных эритроцитов включает соль натрия, глюкозу и аденин, а в качестве соли натрия - фумарат натрия и смесь одно- и двузамещенных фосфатов натрия, а также сахарозу для повышения осмолярности раствора, причем компоненты взяты в следующем соотношении (в миллимолях на литр): 46,3±6,9 фумарата натрия, 12,2±4,5 однозамещенного фосфата натрия, 10,5±3,6 двузамещенного фосфата натрия, 40,4±0,1 глюкозы, 1,47±0,01 аденина и 88,8±1,7 сахарозы. Раствор может дополнительно включать 4,3±0,5 мМоль/л цитрата натрия. Предлагаемый добавочный раствор эффективен при гипотермическом хранении отмытых размороженных эритроцитов, сохраняет их количество и функциональную активность во всем периоде хранения. 1 ...

Способ лечения аневризмы подколенной артерии

Изобретение относится к медицине, а именно к сосудистой хирургии, и может быть использовано в хирургическом лечении аневризм подколенных артерий. Осуществляют лигирование ложной аневризмы, выделяют проксимальную порцию подколенной артерии доступом в нижней трети бедра по линии Кена; дистальную порцию подколенной артерии тибиомедиальным доступом в верхней трети голени. Формируют последовательные анастомозы линейного аллографта и подколенной артерии. Для протезирования подколенной артерии применяется аллотрансплантат подколенной артерии, который забирается у посмертного донора при мультивисцеральном заборе и кондиционируется в растворе для культивации клеточных структур Roswell Park Memorial Institute 1640 c добавлением гентамицина в концентрации 400 мкг/мл и флуконазола в концентрации 20 мкг/мл при температуре +4°С. Способ позволяет улучшить результаты хирургического лечения больных с аневризмами подколенных артерий: избежать тромботических осложнений, развития критической и острой ишемии ...

Автоматизированное устройство для нормотермической перфузии изолированной донорской печени

Полезная модель относится к области медицинской техники для трансплантологии и представляет собой автоматизированное перфузионное устройство со средствами бесконтактной гидродинамической сенсорики, предназначенное для реабилитации и поддержания жизнеспособности изолированной донорской печени.Устройство включает центробежные насосы с высоким КПД, которые создают перфузионный поток с малой травмой форменных элементов крови. Насыщение крови кислородом реализуется с помощью стандартного оксигенатора. Устройство дренажа пузырей и датчик наличия пузырей не допускают блокирование каналов печени пузырями, а встроенный PH-метр при обнаружении высокого содержания углекислоты, и соответственно и высокой концентрации углекислого газа, вводит необходимый медикаментозный препарат в венозную артерию с помощью шприцевого дозатора. Это позволяет улучшить обмен газами в оксигенаторе и приводит уровень углекислого газа в норму. Наличие неинвазивных датчиков расхода и инвазивных датчиков давления позволяет ...

Автоматизированное устройство для нормотермической перфузии изолированной донорской печени

Полезная модель относится к области медицинской техники для трансплантологии и представляет собой автоматизированное перфузионное устройство со средствами бесконтактной гидродинамической сенсорики, предназначенное для перфузии изолированной донорской печени, для восстановления и поддержания ее жизнеспособности.Полная автоматизация процесса перфузии изолированной донорской печени достигается за счет того, что в устройство дополнительно введена автоматическая система выбора источника кислорода, управляющая регулируемым воздушным дросселем и воздушным компрессором, соединенными между собой тройником с обратными клапанами. При этом вход системы выбора источника кислорода соединен через перекидной клапан с запасным баллоном и штуцером для подключения внешней магистрали, а выход системы соединен с оксигенатором. Кроме того, в устройство ввода медицинских препаратов дополнительно введены инфузионные шприцевые дозаторы, оборудованные механизмами поступательного движения и сенсорами, позволяющими ...

УСТРОЙСТВО ДЛЯ ТЕМПЕРИРОВАНИЯ И СПОСОБ ТЕМПЕРИРОВАНИЯ

Изобретение относится к устройству для размораживания и регулирования температуры продукта. Предложено устройство для размораживания и регулирования температуры выполненного текучим или в виде геля, расположенного в оболочке и замороженного продукта (1), имеющее корпус (2), в котором содержатся терморегулируемый продукт (1), нагревательный модуль (10) для передачи тепла по меньшей мере с одной стороны (15, 15') терморегулируемого продукта (1), исполнительный орган, посредством которого терморегулируемый продукт (1) может приводиться в движение, при этом этот исполнительный орган выполнен в виде механического исполнительного элемента, который распространяется, идеально прилегая непосредственно к терморегулируемому продукту (1), и который может активироваться таким образом, что он совершает периодическое и/или непериодическое движение, причем исполнительный элемент через связанный актуатор может активироваться таким образом, что исполнительный элемент поворачивается относительно оси (S) поворота ...

СПОСОБ ЗАМОРАЖИВАНИЯ КРАСНЫХ КРОВЯНЫХ КЛЕТОК И РАМА ДЛЯ ЗАМОРАЖИВАНИЯ КРАСНЫХ КРОВЯНЫХ КЛЕТОК

Использование: для замораживания красных кровяных клеток с целью их долговременного хранения без потери их свойств. Сущность изобретения: способ замораживания стандартного объема донорской крови для значительного хранения и последующего получения чистого материала для переливания, который предполагает ее центрифугирование для отделения красных кровяных клеток от плазмы и тромбоцитов до объема глобулярной массы последних не менее 90%, перенос красных кровяных клеток в мешок для замораживания, содержащий оксиэтиловый крахмал ОЭК при соотношении веса ОЭК к объему красных кровяных клеток не более 7%, предпочтительно 6%. Устройство выполнено в виде рамы для размещения мешка с замораживаемой смесью (жидкий азот). Рама состоит из двух дугообразных перфорированных алюминиевых пластин, закраины которых изогнуты навстречу друг другу и являются направляющими для плоско-параллельного перемещения пластин. Пластины скреплены прижимными элементами из упругого материала. 2 с. и 8 з.п. ф-лы, 4 ил.

КРИОПРОТЕКТОР ДЛЯ ЦЕЛЬНОЙ КРОВИ

Изобретение относится к медицине, а именно к созданию криопротекторного раствора для хранения крови. Криопротектор для замораживания цельной крови при субумеренно низкой -20°С и умеренно низкой -40°С температурах включает глицерин, натрия хлорид, натрия фосфат двузамещенный, воду для инъекций и дополнительно диметилсульфоксид и лактулозу при следующем соотношении ингредиентов, об. %: глицерин 20, диметилсульфоксид 10, лактулоза 2,5, натрия хлорид 0,25; натрия фосфата двузамещенный 0,25; вода для инъекций до 100%. Предлагаемый криопротектор для цельной крови обеспечивает сохранение морфофункциональной цельности клеток крови в условиях субумеренно и умеренно низких температур. 5 пр.

Способ получения вазорентгенограммы сосудистого русла рыбы

Изобретение может быть использовано для изучения морфологических особенностей архитектоники сосудистого русла рыб, при проведении фундаментальных исследований по их анатомии и сравнительной морфологии. Способ включает приготовление раствора путем смешивания разбавителя №1 завода художественных красок «Невская палитра» и художественной масляной краски из натурального пигмента «Ультрамарин желтый» компании «Звездный цвет» в пропорции 1:1. Полученным раствором заполняют сосудистое русло рыбы через хвостовую вену и проводят рентгенографию. Изобретение обеспечивает получение вазорентгенограмм сосудистого русла рыбы. 1 ил.

Способ подготовки биологической ткани для трансплантации

Настоящее изобретение относится к области медицины, в частности хирургии, а именно к способу подготовки биологической ткани для трансплантации. Для осуществления способа подготавливают консервирующий раствор путём смешения 100 мл эмульсии перфторана и 2 г Цефтриаксона. Затем консервирующий раствор помещают в аппарат Боброва, через который со скоростью 2-4 л/мин подается чистый кислород в течение 15-30 минут. Одновременно подготавливают иссеченный аутодермальный трансплантат, деэпителизируя и перфорируя его в шахматном порядке, с диаметром перфорации 0,3-0,4 см, с последующим помещением трансплантата в приготовленный консервирующий раствор на 40-60 минут. Настоящее изобретение позволяет сохранить физические свойства кожного трансплантата, повышая его антибактериальную активность в ранние сроки после имплантации, и обеспечивает приживление трансплантата в процессе регенерации. 2 пр.

РАЗМОРАЖИВАЮЩАЯ ЖИДКОСТЬ, СПОСОБ ЕЕ ПРИГОТОВЛЕНИЯ И ЕЕ ПРИМЕНЕНИЕ

Изобретение относится к области сохранения биологического материала, в частности, размораживанию криоконсервированных клеток или тканей. Размораживающий раствор содержит на 100 мл: 0,1-50 г биомиметического материала для подавления нарастания льда, водорастворимый сахарид в концентрации 0-1,0 моль/л, и остальное составляет буфер. Биомиметический материал для подавления нарастания льда представляет собой атактический поливиниловый спирт (ПВС), имеющий синдиотактичность, составляющую 15-65%, молекулярную массу 10-500 кДа, или комбинацию указанного атактического поливинилового спирта (ПВС), аминокислоты, полипептида и/или полиаминокислоты. Аминокислота выбрана из одного из или комбинации двух или более из аргинина, треонина, пролина, лизина, гистидина, глутамина, аспарагиновой кислоты, глицина. Полипептид представляет собой одно или более из L-Thr-L-Arg (TR), L-Thr-L-Pro (TP), L-Arg-L-Thr (RT), L-Pro-L-Thr (PT), L-Thr-L-Arg-L-Thr (TRT), L-Thr-L-Pro-L-Thr (TPT) или L-Thr-L-Cys-L-Thr (TCT).

Способ приготовления препаратов из полученных in vivo мембран сетчатки глаза

Изобретение относится к области офтальмологии, а именно к способу приготовления препаратов из полученных in vivo мембран сетчатки глаза. Способ приготовления препаратов из полученных in vivo мембран сетчатки глаза, включающий фиксацию биологического материала в 10%-ном растворе нейтрального формалина, заливку материала в парафин, и последующее изготовление срезов на микротоме, при этом, препарат после фиксации в формалине и до заливки в парафин, с помощью шпателя извлекают из раствора формалина и помещают на парафиновую пленку, затем с помощью шпателя и пинцета мембрана сетчатки глаза ориентируют на поверхности парафиновой пленки так, чтобы сохранялась нормальная анатомия и топографические взаимоотношения частей препарата, затем края мембраны фиксируют к парафиновой пленке путем вставления в края мембраны игл для шприцов калибра 27 Гейдж (27G, 0,417 мм), приготовленный таким образом препарат заливают парафином, после чего дожидаются его затвердевания, удаляют иглы и изготавливают срезы ...

Способ производства гамма-глобулинового полуфабриката с повышенным содержанием противовирусных антител из боенской крови вакцинированных коров

Изобретение относится к биологической промышленности, в частности к способу получения гамма-глобулинового полуфабриката из боенской крови крупного рогатого скота. Способ получения гамма-глобулинового полуфабриката из боенской крови крупного рогатого скота с помощью химических реагентов, при этом в качестве сырья используется боенская кровь по месту ее заготовки и сепарирования в условиях мясокомбината, а образцы плазмы по мере их изготовления помещаются в насыщенный 100% от насыщения или 4,05 М раствор сульфата аммония с 0,75% дидецилдиметиламмония хлорида, в соотношении раствор : плазма 1:1,5 по объему, до концентрации 40% от насыщения сульфата аммония и 0,3% дидецилдиметиламмония хлорида, образовавшуюся суспензию центрифугируют с получением осадка гамма-глобулиновой фракции, в образовавшийся надосадок добавляют при перемешивании сухой порошок сульфата аммония, получая конечную концентрацию сульфата аммония 75% от насыщения, и доводят рН до 4,6, суспензию перемешивают и центрифугируют, ...

СПОСОБ КОНСЕРВАЦИИ ДОНОРСКОГО СЕРДЦА

Изобретение относится к области биотехнологии, а именно к консервации донорского сердца. Способ включает канюлирование аорты сердца, находящегося в охлажденном до +2-4°С растворе Кребса-Хензелайта, насыщенном карбогеном (95% О2+ 5% СО2), располагая дистальный конец канюли выше уровня отхождения устьев коронарных артерий. Затем канюлю фиксируют лигатурой и осуществляют непрерывную инсуффляцию коронарного русла при закрытом аортальном клапане увлажненным кислородом под постоянным давлением 35 мм рт.ст. с объемной скоростью 3 мл/мин на период до 24 часов. Изобретение позволяет сохранить жизнеспособность сердца на 24 часа за счет обеспечения непрерывной оксигенации донорского сердца в условиях снижения его метаболических потребностей. 1 пр.

Способ изготовления органокомплекса гортани и щитовидной железы человека

Изобретение относится к медицине, а именно к нормальной и топографической анатомии, и может быть использовано для изготовления органокомплекса гортани и щитовидной железы человека. Производят последовательное обезжиривание, подсушивание и экспозицию. Органокомплекс препарируют путем удаления кожи, подкожной клетчатки, поверхностной фасции, поверхностного и глубокого листков собственной фасции, париетального листка внутришейной фасции и периорганной клетчатки. Отпрепарированный органокомплекс помещают для обезжиривания на 5 суток при комнатной температуре в состав А, состоящий из равных частей ацетона и бензина, причем объем состава А должен превышать объем органокомплекса в 5 раз. После чего органокомплекс подсушивают и экспонируют в составе Б, состоящем из 3/5 частей уайт-спирита и 2/5 бесцветного силикона при температуре 40 градусов в течение 2 суток, объем состава Б - более объема органокомплекса в 2 раза. Затем после подсушивания, путем подвешивания органокомплекса, при комнатной температуре ...

ПРИРОДНЫЕ КЛЕТКИ-КИЛЛЕРЫ И ИХ ПРИМЕНЕНИЕ

... 1. Выделенная популяция предшественников природных клеток-киллеров (NK), где указанные предшественники NK-клеток получают способом, включающим: (i) культивирование гемопоэтических стволовых клеток или клеток-предшественников в первой среде, содержащей Flt3L, ТРО, SCF, IL-7, G-CSF, IL-6 и GM-CSF, (ii) последующее культивирование указанных клеток во второй среде, содержащей Flt3L, SCF, IL-15 и IL-7, IL-17 и IL-15, G-CSF, IL-6 и GM-CSF, и (iii) последующее культивирование указанных клеток в третьей среде, содержащей SCF, IL-15, IL-7, IL-2, G-CSF, IL-6 и GM-CSF.2. Выделенная популяция предшественников NK-клеток по п. 1, где продолжительность стадии культивирования (i) составляет 7-9 дней; продолжительность стадии культивирования (ii) составляет 5-7 дней, а продолжительность стадии культивирования (iii) составляет 5-9 дней.3. Выделенная популяция предшественников NK-клеток по п. 1, где продолжительность стадии культивирования (i) составляет 7-9 дней; продолжительность стадии культивирования ...

НЕОРГАНИЧЕСКИЙ ПИРОФОСФАТ И ЕГО ПРИМЕНЕНИЕ

... 1. Среда для консервации спермы, содержащая неорганический пирофосфат (PPi).2. Среда для консервации спермы по п. 1, где концентрация PPi находится в пределах примерно между 1 мкМ и примерно 200 мкМ.3. Среда для консервации спермы по п. 1, где концентрация PPi находится в пределах примерно между 1 мкМ и примерно 20 мкМ.4. Среда для консервации спермы по п. 1, где концентрация PPi составляет примерно 10 мкМ.5. Среда для консервации спермы по п. 1, где указанная среда для консервации используется для консервации спермы свиней.6. Среда для обработки спермы, содержащая неорганический пирофосфат (PPi).7. Среда по п. 6, где концентрация PPi находится в пределах примерно между 1 мкМ и примерно 200 мкМ.8. Среда по п. 6, где концентрация PPi находится в пределах примерно между 1 мкМ и примерно 20 мкМ.9. Среда для оплодотворения in vitro (IVF) или искусственного осеменения (AI), содержащая неорганический пирофосфат (PPi).10. Среда по п. 9, где концентрация PPi находится в пределах примерно между ...

УСТРОЙСТВО ДЛЯ ТРАНСПОРТИРОВКИ И/ИЛИ ХРАНЕНИЯ, СОДЕРЖАЩЕЕ ИЗОЛИРУЮЩИЙ БАЛЛОН С ДВОЙНОЙ СТЕНКОЙ

... 1. Устройство (10) для транспортировки и/или хранения продуктов в частности криостатного типа, имеющее внешнюю упаковочную конструкцию (14), содержащую стенки, определяющие внутренний объем (16), в котором расположен изолирующий баллон (12) с двойными стенками, тело (32) которого образовано наружной стенкой (34) и внутренней стенкой (36), определяющей внутренний объем (38), причем баллон (12) имеет верхнюю горловину (40), определяющую верхнее наливное отверстие (42), и устройство (10) содержит средства (46) поддержки баллона (12), которые содержат крепежные средства (48), способные входить в зацепление только с внутренней стенкой (36) баллона (12), чтобы подвешивать баллон (12) вертикально за его горловину (40) так, чтобы баллон (12) свободно висел в пустом пространстве внутри внутреннего объема (16), определяемого упаковочной конструкцией (14, 18, 22), без контакта между наружной стенкой (34) баллона (12) и стенками (24, 22) упаковочной конструкции (14), и причем упомянутое устройство ...

СПОСОБ И УСТРОЙСТВО ДЛЯ РАЗМОРАЖИВАНИЯ БИОЛОГИЧЕСКОГО МАТЕРИАЛА

... 1. Способ размораживания замороженного биологического материала, содержащий этапы, на которыхсчитывают информацию, содержащуюся на коде или метке, ассоциированной с замороженным биологическим материалом;задают целевую температуру для замороженного биологического материала;применяют нагрев к замороженному биологическому материалу посредством нагревательного устройства; иуправляемым образом перемещают биологический материал в течение периода времени, чтобы предоставлять возможность, в целом, равномерного рассеяния тепла, при этом период времени определяется на основе, по меньшей мере, одного из целевой температуры и объема содержимого биологического материала.2. Способ по п. 1, при этом замороженный биологический материал включает в себя взвесь популяции клеток.3. Способ по п. 2, при этом популяция клеток включает в себя эукариотические клетки.4. Способ по п. 1, при этом замороженный биологический материал размещается в пробирке, а нагревательное устройство конфигурируется для приема упомянутой ...

Способ хранения почки поросенка для получения монослоя первичнотрипсинизированных клеток и использования его в вирусологических исследованиях

Изобретение относится к области биотехнологии. Изобретение представляет собой способ хранения почек поросят при субнормальных температурах (0÷4°C) от 2 до 7 суток для получения монослоя первично трипсинизированных культур. Изобретение позволяет увеличить длительность хранения изолированной почки. 2 з.п. ф-лы, 5 пр., 3 табл., 5 ил.

СПОСОБ КРИОПРОТЕКЦИИ СВОБОДНОПЛАВАЮЩИХ СРЕЗОВ МОЗГА ДЛЯ ИММУНОГИСТОХИМИЧЕСКОГО ИССЛЕДОВАНИЯ

Изобретение относится к химико-фармацевтической промышленности и представляет собой способ криопротекции свободноплавающих срезов мозга для иммуногистохимического исследования, включающий фиксирование срезов мозга в растворе формальдегида, помещение их в раствор на основе фосфатно-солевого буфера NaCl, Na2HPO4 и NaH2PO4 с криопротектором и хранение при пониженной температуре, отличающийся тем, что в качестве криопротектирующего вещества в раствор добавляют глицерин в объемном соотношении 50:50. Изобретение позволяет создать более экономический способ криопротекции срезов мозга и менее трудоемкий процесс его приготовления из-за уменьшения числа компонентов криопротектирующего раствора. 2 ил., 1 пр.

СРЕДА ДЛЯ ХРАНЕНИЯ КЛЕТОК

... 1. Способ кратковременного хранения клеток животных, в котором эти клетки помещают в жидкую клеточную среду, содержащую ! а) солевой раствор, выбранный из ! солевого раствора, содержащего, в частности, хлорид натрия, глюконат натрия, ацетат натрия, хлорид калия, хлорид магния и цитрат натрия, ! раствора Рингера-лактата и ! забуференного фосфатом солевого раствора (ЗФР), ! и/или водный раствор высокомолекулярного сахара, в частности гидроксиэтилкрахмала, ! b) глюкозу и ! с) сывороточный альбумин и/или плазму крови, ! и хранят в этой клеточной среде. ! 2. Способ по п.1, в котором эти клетки являются криоконсервированными клетками, и их оттаивают (размораживают) и после оттаивания промывают в указанной клеточной среде, отделяют от клеточной среды и затем помещают в свежую клеточную среду для хранения. ! 3. Способ по одному из предыдущих пунктов, в котором эта клеточная среда имеет температуру 2-40°С. ! 4. Способ по п.1, где в случае этих клеток речь идет о клетках печени. ! 5. Способ по п.4 ...

СПОСОБ КОНСЕРВИРОВАНИЯ ПАНТОВ МАРАЛОВ

Способ консервирования пантов маралов, включающий сортировку пантов на три группы по величине обхвата главного ствола между вторым и третьим отростками соответственно 12-15, 16-18, 19-21 см, двухдневную варку пантов путем погружения в горячую воду с отдыхом-остыванием после каждого погружения и чередованием ветровых и жаровых сушек, отличающийся тем, что варку всех трех групп пантов осуществляют раздельно путем трехкратного погружения пантов в воду с температурой 93-96°C, а время погружения и время отдыха остывания пантов с обхватом ствола 12-15 см составляют 90 и 90 с, для пантов с обхватом ствола 16-18 см - 105 и 105 с, для пантов с обхватом ствола 19-21 см - 120 и 120 с соответственно, при этом первую жаровую сушку проводят при температуре 70°C, вторую через два дня при температуре 65°C и третью через четыре дня после второй при температуре 60°C, а все ветровые сушки осуществляют при 8-10°C, причем и ветровые, и жаровые сушки проводят при принудительной подаче воздуха со скоростью 10 ...

СПОСОБ КОНСЕРВАЦИИ ЭРИТРОЦИТОВ

КОМПОЗИЦИЯ ПУПОВИННОЙ КРОВИ (ВАРИАНТЫ), СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ

... 1. Композиция пуповинной крови, содержащая, по меньшей мере, около 50 об.% эритроцитов и антикоагулянт, отличающаяся тем, что плазма в значительной степени удалена с сохранением при этом эритроцитов. ! 2. Композиция по п.1, отличающаяся тем, что содержит, по меньшей мере, около 65 об.% эритроцитов. ! 3. Композиция по п.1, отличающаяся тем, что содержит около 0-30 об.% плазмы. ! 4. Композиция по п.1, отличающаяся тем, что содержит стволовые клетки. ! 5. Композиция по п.4, отличающаяся тем, что стволовые клетки являются гемопоэтическими (кроветворными) стволовыми клетками. ! 6. Композиция по п.1, отличающаяся тем, что содержит около 5-40 об.% антикоагулянта. ! 7. Композиция по п.6, отличающаяся тем, что содержит около 5-20 об.% антикоагулянта. ! 8. Композиция по п.1, отличающаяся тем, что антикоагулянт выбран из группы, состоящей из лимонной кислоты, цитрата натрия, фосфата натрия, декстрозы, аденозина и их смесей. ! 9. Композиция по п.1, дополнительно содержащая криопротектор. ! 10. Композиция ...

СПОСОБ И СИСТЕМА ПРИГОТОВЛЕНИЯ ОБРАЗЦОВ ТКАНЕЙ ДЛЯ ГИСТОЛОГИЧЕСКОГО И ПАТОЛОГИЧЕСКОГО ИССЛЕДОВАНИЯ

... 1. Способ, предусматривающий замораживание образца биохимически активной ткани, причем замораживание включает погружение образца ткани в охлаждающую среду, циркулирование охлаждающей среды вокруг образца ткани при по существу постоянной заданной скорости и температуре для замораживания образца ткани так, чтобы образец ткани витрифицировался и при этом образец ткани сохраняет свою анатомическую структуру и остается биохимически активным после размораживания, размораживание образца ткани, и исследование размороженного образца ткани. 2. Способ по п.1, дополнительно предусматривающий приготовление срезов образца ткани. 3. Способ по п.1, в котором исследование образца размороженной ткани включает гистологическое исследование. 4. Способ по п.1, в котором исследование размороженного образца ткани включает ультраструктурное исследование. 5. Способ по п.1, в котором исследование включает использование иммуногистохимического исследования. 6. Способ по п.5, в котором иммуногистохимическое исследование ...

СПОСОБ ХРАНЕНИЯ ОРГАНОВ МЛЕКОПИТАЮЩИХ

... 1. Способ хранения органов млекопитающих, предусматривающий стадии удаления воды из органа, имеющего физиологически нормальное содержание воды, через сосудистую систему органа, посредством чего удаляют по меньшей мере приблизительно 10 мас.% воды по отношению к общей массе органа перед обезвоживанием, но оставляют приблизительно 10-20 мас.% воды по отношению к общему содержанию воды перед обезвоживанием; погружения указанного органа в инертную среду; и хранения указанного органа при температуре холодильника. 2. Способ хранения сердца млекопитающего, предусматривающий стадии удаления крови из сердца путем промывания физиологическим солевым раствором до замещения крови в сердце на физиологический солевой раствор; удаления воды из промытого сердца путем извлечения воды через кровеносную сосудистую систему сердца, посредством чего удаляют приблизительно 10-50 мас.% воды по отношению к общей массе сердца перед обезвоживанием, погружения указанного сердца в инертную среду; и хранения указанного ...

Способ приготовления и сохранения просветленных анатомических препаратов

Изобретение относится к области медицины, а именно к топографической анатомии. Предлагается способ приготовления и сохранения просветленных анатомических препаратов, включающий препарирование анатомического материала и его фиксацию в 10 об. % растворе нейтрального формалина, согласно изобретению проводят дегидратацию и обезжиривание материала с помощью технического ацетона, объекты толщиной до 10 мм выдерживают в ацетоне трое суток, при этом каждые сутки ацетон заменяют, затем материал просветляют нефтяным ксилолом в течение трех суток с ежедневной сменой ксилола, после чего оставляют в четвертой порции ксилола на 30 суток, а объекты толщиной более 10 мм, целые органы, органокомплексы выдерживают шесть суток в трех порциях ацетона, при этом ацетон заменяют один раз в двое суток, затем материал просветляют нефтяным ксилолом, выдерживая материал шесть суток в трех порциях ксилола, при этом ксилол заменяют один раз в двое суток, после чего оставляют в четвертой порции ксилола на 60 суток, ...

КОМПОЗИЦИИ И СПОСОБЫ КРИОКОНСЕРВАЦИИ КЛЕТОК

Изобретение относится к биотехнологии. Предложена среда для криоконсервации иммунных клеток млекопитающих, содержащая от около 1 до 10 % масс./об. диметилсульфоксида (ДМСО), от около 0,25 до 5 % масс./об. дисахарида и сывороточный альбумин человека, а также способы криоконсервации иммунных клеток млекопитающих с использованием данной среды и содержащий ее набор. Замороженные и размороженные клетки с использованием сред и способов по настоящему изобретению сохраняют высокую выживаемость, что позволяет использовать клетки для различных применений, включая, например, способы адоптивного переноса клеток. 7 н. и 37 з.п. ф-лы, 15 ил., 4 табл., 6 пр.

Isolated heart perfusion appts. - has closed vessel with fluid and adjustable gas vol. to give timed aorta pressure

The appts. has a feed channel (16b, 16c) interrupted by a closed vessel (31) partially filled with fluid and partially with gas. The gas vol. is adjustable in the vessel (31). Pref. the vessel (31) has a passage drilling (38) near the liq. filler, with a closure held against its outlet at a defined pressure so that, when the pressure is exceeded, liq. can move out of the vessel (31). Fluid moving out of the vessel (31) passes through a return channel (45) back to the reservoir. The drilling (38) outlet is covered by an elastic membrane against a chamber with a defined inner pressure, and the edges of the membrane are sealed against a plate with a second drilling (38) to the other (39) within the membrane cover and out to the return channel (45). The chamber at the outer side of the membrane is connected (55) to a spindle injection (56) piston/cylinder (58,57) system to set the chamber pressure. A manometer (61) shows the chamber pressure at the rubber membrane. The plate for the drillings ...

Biologische Kryoprotektion.

VERFAHREN ZUR TIEFTEMPERATURKONSERVIERUNG VON SPERMA

IN HOHEM MASSE FLUORIERTE, CHLORSUBSTITUIERTE ORGANISCHE VERBINDUNGEN ENTHALTENDE EMULSIONEN UND METHODEN ZU DEREN HERSTELLUNG UND VERWENDUNG

KRYOSPEICHEREINRICHTUNG MIT TRANSPONDER

VERFAHREN ZUM EINFRIEREN VON ROTEN BLUTKÖRPERCHEN.

Vorrichtung zum Tiefgefrieren von in Gefässen eingeschlossenen Proben biologischen Materials.

Verfahren zur Preservierung von Zellen, Gewebe und Organen

Künstliche Sauerstoffträger und ihre Verwendung

Die Erfindung betrifft Dispersionen von künstlichen Sauerstoffträgern, wobei die Dispersionen Kapseln mit reversibler Sauerstoffspeicherfähigkeit enthalten, wobei die Kapseln ein sauerstoffpermeables Kapselmaterial umfassen, welches fluorierte, insbesondere perfluorierte Kohlenwasserstoffe, vorzugsweise Perfluorcarbone, enthält und/oder einschließt. Die Dispersionen eignen sich insbesondere als Blutersatzstoff, vorzugsweise zu Zwecken der Transfusion, z.B. bei Zuständen nach Blutverlusten des menschlichen oder tierischen Körpers, insbesondere nach operativen Eingriffen, Unfällen, Verletzungen etc., oder zur prophylaktischen und/oder therapeutischen Behandlung von ischämischen Zuständen oder von Zuständen nach Reperfusion.

Katheterset zum Konservieren von Herz und inneren Organen für Transplantationen

Scleroprotein e.g. collagen, keratin or elastin transplants prodn. - involving treatment with glycerol or polyethylene glycol to improve biological stability

In a new procedure for the prodn. of scleroprotein transplants with improved biological stability from raw human or animal scleroprotein by treating with water, treating with hydrogen peroxide, defatting, washing and sterilising, the scleroprotein is treated with glycerol or polyethylene glycol after washing but before drying. The glycerol or polyethylene glycol treatment gives improved resistance to biological degradation. The transplants are soft, and do not require rehydration before use. The prod. is transparent so that e.g. in brain operations the biological fluids and brain can be viewed through the transplantate. The glycerol or polyethylene glycol (pref. molecular weight 400-2000) is pref. used in the form of an aqueous 5-50% solution. When the scleroprotein is human dura, it is particularly advantageous to use a 20-40% (esp. 30%) soln. of glycerol in water.

New vessel including a cryopreserved epidermal transplant useful in treatment of burns, is composed of a flexible, non-cytotoxic plastic

A vessel, with a sealable opening, prepared from a flexible plastic which is non-toxic to cells, is new and comprises a cryopreserved epidermal transplant.

Verfahren und Vorrichtung zur Kryokonservierung biologischer Proben

Verfahren zur Kryokonservierung biologischer Proben (1), mit den Schritten: – Ablage der Proben (1) in einem flüssigen Zustand mit einem Flüssigkeitsförderwerkzeug (50) von einem Probenreservoir (30) auf eine Oberfläche eines Substrates (10), wobei die Oberfläche des Substrates (10) flüssigkeitsanziehende Bereiche (11) mit einer geometrischen Anordnung aufweist, die durch flüssigkeitsabstoßende Bereiche (12) voneinander getrennt sind,, und – Abkühlung der Proben (1) in einen gefrorenen Zustand mit einer Kühleinrichtung (20), dadurch gekennzeichnet, dass – als Substrat eine Folie verwendet wird, deren Oberfläche die flüssigkeitsanziehenden und flüssigkeitsabstoßenden Bereiche (11, 12) bildet, – die Proben (1) mit dem Flüssigkeitsförderwerkzeug (50) auf die Oberfläche des Substrats (10) unter der Wirkung der Schwerkraft aufgegossen oder aufgetropft werden, und – die Ablage eine Verteilung der Probensuspension (2) durch eine Benetzung der Oberfläche der Folie ist, dergestalt dass die Probensuspension ...

CONTROLLED REDUCTION IN TEMPERATURE AND PRESERVATION OF EMBRYOS

Method for low-temperature preservation of embryos

The method consists in cooling of embryos down to the temperature of the refrigerant in a buffer-salt fluid, the cooling process being carried out in a temperature diffusive powdered material that has preliminarily been cooled down to the refrigerant temperature. The buffer-salt fluid comprises a mixture of cryoprotectors, i.e., glycerol, dimethylsulphoxide, and a dihydric alcohol. An example of the temperature diffusive material is powdered metal.

Solutions for the perfusion, preservation and reperfusion of organs

Solution for the perfusion, preservation and reperfusion of organs

Method and apparatus for cryopreservation

A method of cryopreserving biological material, which method comprises providing a sample of the biological material, where a liquid phase of the sample includes at least one solute; lowering the temperature of the sample to a nucleating point at which ice nucleation can occur in the sample; effecting ice nucleation in the sample; and lowering the sample temperature from the nucleating point to the solidification point thereof, characterised in that the temparature lowering from the nucleating point to the solidification point is non linear, whereby the rate of change of solute concentration in the liquid phase decreases for more than 80 % of the time taken to lower the temperature from the nucleating point to the solidification point.

Protection means for freezing process

Weighted cell beads for fluidised bed culture for bioartificial liver

A scalable method for the culture of cells in a fluidised bed bioreactor is disclosed wherein hepatocytes or other cells are encapsulated in alginate or an alternative matrix in the presence of bead density or buoyancy modifying additives such as glass beads. The encapsulation comprises seeding a matrix forming agent with cells, adding the density modifiers, streaming the mixture through a nozzle and cutting the stream into beads for polymerisation (e.g. JetCutter bead extrusion technology). Alginate encapsulated HepG2 cells comprising glass particles such that the beads are weighted to be buoyant in an upward current in human plasma are disclosed. Also disclosed is a chamber for a bio-artificial liver configured for perfusive culture and cryopreservation.

Methods for conducting cellular assays

Oxygen supply for organ perfusion systems

A desiccated product

Body tissue preservation system and method

COMPOSITION AND METHOD FOR PRESERVING ERYTHROCYTES

Preservation solutions

Composition for organ cryopreservation and treatment of viral and bacterial infection

The invention provides a method for the cryopreservation of organs and the treatment of viral and/or microbial infections, the substance or composition comprising an active agent selected from the group consisting of amides of the general formula r3-co-nr1r2, in which: r1 and r2 are independently selected from the group including h, me, halomethyl, saturated and unsaturated c2-c3 alkyl groups, saturated and unsaturated halogenated c2-c3 alkyl groups, hydroxylated alkyl groups; or r1 and r2 are together selected from (ch2)n, wherein n= 4 or 5, or (ch2)2o(ch2)2; and r3 is selected from h, me and saturated and unsaturated c2-c3 alkyl groups.

Container.

A portable container (10)for receiving contents for transport whilst regulating the temperature of the contents comprises combined heating and/or cooling means in the form of a peltier effect device (50), a removable inner receptacle (70)for receiving the contents, an air gap around the outside of the inner receptacle, and a control unit (62)for controlling the peltier effect device so as to regulate the temperature of the air around the outside of the inner receptacle and thereby regulate the temperature of the contents of the inner receptacle. The control unit can have a temperature logging system for recording the temperature history of the contents of the container.

Container

METHOD FOR PRESERVING TRANSPLANTABLE SHEETS OF EPITHELIUM CULTURED IN VITRO

Method for preservation of living organic by freezing.

Process and apparatus for the conservation of biological substances, in particular total blood.

Composition for organ cryopreservation and treatment of viral and bacterial infections

Composition for organ cryopreservation and treatment of viral and bacterial infections

ANALYSIS OF CIRCULATING TUMOR CELLS, FRAGMENTS AND RUBBLE

PROCEDURE AND ARRANGEMENT FROM BAGS TO THE CONCENTRATION OF WHITE CELLS

CARRIER FOR A SAMPLE CHAMBER, IN PARTICULAR TO KRYOKONSERVIERUNG BIOLOGICAL SAMPLES

KRYOSPEICHEREINRICHTUNG WITH TRANSPONDER

LÖSUNGEN FÜR DIE PERFUSION, KONSERVIERUNG UND REPERFUSION VON ORGANEN

STORAGE DEVICE FOR THE FREEZING PRESERVATION OF BIOLOGICAL SAMPLES

USE FROM DURCHFLUSSZYTOMETRI ANALYSIS TO THE OPTIMIZATION OF ZELLBANKINGSTRATEGIEN FOR CHO CELLS

ARRANGEMENT FOR PACKING A PRE-DETERMINED MATERIAL VOLUME FOR KEEPING BY CRYOGENIC GLAZING

PROCEDURE FOR THE TRANSPORT OF CELLS AND TRANSPLANTS

PROCEDURE FOR THE PRODUCTION OF FREEZINGDRIED BLOOD PANEL, FREEZINGDRIED BLOOD PANELS CONTAINING COMPOSITIONS AND USE PROCEDURES

LÖSUNG ZUR PERFUSION, KONSERVIERUNG UND REPERFUSION VON ORGANEN

PRODUCTION OF A VIABLEN, STORABLE ONE WORM EGG SUSPENSION

APPARATUS FOR THE EXTENSION OF THE DURATION OF SURVIVAL OF BLOOD PANELS

THE UNDERCOOLING PROMOTING MEANS

KÜHLUND FREEZING EQUIPMENT FOR HUMAN, ANIMAL OR VEGETABLE CELL MATERIAL

PROCEDURE FOR THE PRODUCTION OF STABLE BLOOD PLASMA

PROCEDURE FOR THE ISOLATION FROM MAIN CELLS A KISSENFORMIGES FABRIC OF THE TEETH

LÖSUNG ZUR PERFUSION, KONSERVIERUNG UND REPERFUSION VON ORGANEN

SOLUTION FOR THE ORGAN PRESERVATION

PROCEDURE FOR FREEZING FABRIC.

PROCEDURE AND DEVICE FOR THE PRESERVATION OF ORGANS, EXTREMITIES AND FABRIC RAGS

COMPOSITION AND PROCEDURE FOR THE BLOOD PRESERVATION

FREEZING PROCESS OF VITAL BODY FLUIDS.

PROTEKTIVE LOESUNG FOR HEART AND KIDNEY AND PROCEDURE FOR THEIR PRODUCTION.

PRESERVATION THROUGH KUEHLUNG.

BY HEAT STERILIZE-CASH CAMP SOLUTION FOR RED BLOOD CELLS AND BLUTSAECKE, IT CONTAINING.

DEVICE FOR THE LOW FREEZING OF IN CONTAINERS INCLUDING SAMPLES OF BIOLOGICAL MATERIAL.

PERFUSATFLUESSIGKEIT TO THE KEEPING ONE TOO TRANSPLANTING ORGAN AND STORAGE PROCEDURE.

LIVER TRANSPLANT PRESERVATIVE MIXTURE AND A PROCEDURE FOR THE LIVING PERSON PRESERVATION OF THE LIVER TRANSPLANT

In Vitro Generation of Myeloid Derived Suppressor Cells

The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MD-SCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage colony-stimulating factor (M-CSF).

Systems and Methods for Tissue or Organ Removal

A system for tissue or organ removal is provided. The system has an outer bag having an exit end, and an inner bag situated within the outer bag and having an opening capable of receiving an organ or tissue. The inner bag may be sealed to the exit end of the outer bag about its opening. A fluid-tight space may be situated between the outer bag and the inner bag. The space may be designed to accommodate positive pressure which can act on the inner bag to cause the inner bag to evert and expel the organ or tissue. The system may also include an organ receiving component for receiving the organ as it is expelled. Methods for tissue or organ removal is also provided.

Container assembly and method for containing biological graft

A container assembly for containing a biological graft can include a housing member sized to be able to contain the biological graft while keeping the size of an original shape of the biological graft. An aqueous fluid can fill the housing member such that the biological graft is contained in a suspended state in the aqueous fluid.

Container and Supporting Structure for Housing an Organ

An apparatus intended for evaluation, preservation and perfusion of an organ, such as a lung. The apparatus includes a container with a bottom portion, an insert portion and a lid portion. A pulmonary artery tube is intended to be connected to the lung pulmonary artery and a trachea tube is intended to be connected to the trachea of the lungs and bent tube connects the pulmonary artery tube to a circuit for providing a fluid to the pulmonary artery is provided. The circuit includes a pump, an oxygenator, an optional leukocyte-filter, and a holder for connecting the trachea tube to a source of respiration. There is an oxygenator tube set and a leukocyte-filter tube set. A supporting structure for the container comprises a recess sized for enclosing said container and a display panel. Moreover, there are two handles, which may be unfolded into a position for supporting a sterile cloth.

Method for treatment and storage of platelets

Provides are improved methods for storing platelets and compositions that contain stored platelets for use in transfusions. The method entails obtaining a platelet concentrate from blood obtained from an individual and holding the platelet concentrate in at refrigerated temperatures under an atmosphere having a pressure of from 3.5 to 5 bars comprising more than 65% xenon and for at least one week. Also provided is a refrigerated composition that contains a platelet concentrate, wherein the platelet concentrate contains xenon, and wherein the platelet concentrate has been isolated from an individual for at least seven days.

Sperm Diluent Solution and Method for Artificial Insemination Using Same

A sperm diluent of the present invention contains a chelating agent such as EDTA and/or, EGTA, which forms a complex with a calcium ion, in a base diluent. Further, the sperm diluent contains an immunosuppressive factor such as a steroid hormone and/or, a cytokine, which suppresses migration of leukocytes. By diluting frozen sperm with this sperm diluent followed by performing artificial insemination, death of the sperm before fertilization and phagocytosis of the sperm and embryos by leukocytes in the uterus can be suppressed, allowing enhancement of the conception rate and the implantation rate.

Production and use of high pressure for cryopreservation and cryofixation

Methods and devices are described for the concurrent delivery of elevated pressures and low temperatures to a sample, typically but not exclusively a biological sample. A medium that expands on cooling and/or freezing is employed with a sample immersed therein, typically but not exclusively encased in a sample container. Cooling the medium lowers the temperature and applies pressure to the sample such that reduced damage to a typical biosample occurs. Relatively long-lived metastable phases are also produced, including both metastable liquids and solids, without the need for very rapid cooling steps as required in conventional achievement of such metastable phases. Preliminary test data are also presented.

METHOD OF IMPROVING TRANSPLANT FUNCTION USING SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1)

A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant.

Organ cold storage composition and methods of use

The present invention provides compositions and methods for decreasing oxidative damage to an organ during cold storage.

Method of oocyte cryopreservation using antifreeze protein

Disclosed is a method for cryopreserving an oocyte by adding an antifreeze protein to a cryopreservation liquid (equilibrium solution, vitrification solution). The disclosed cryopreservation method of an oocyte minimizes damage to the oocyte, which increases the survival rate of the oocyte after freezing and thawing of the oocyte, and improves a fertilization rate, and a blastocyst development ratio of the oocyte.

Vitrification systems and methods

The embodiments of the invention described herein relate to systems and methods for the vitrification of biological samples. Vitrification is achieved by generating nanodroplets of a solution comprising the biological sample with a means that can be automated and adapted to high-throughput applications.

Apparatus for oxygenation and perfusion of tissue for organ preservation

An apparatus to oxygenate and perfuse a bodily tissue for extracorporeal preservation of the bodily tissue. The apparatus may be used to transport donor organs for transplant. The apparatus includes a pneumatic system, a pumping chamber, and an organ chamber. The pneumatic system is configured for the controlled delivery of fluid to and from the pumping chamber based on a predetermined control scheme. The pumping chamber is configured to diffuse a gas into a perfusate and to generate a pulse wave for moving the perfusate through a bodily tissue. The pumping chamber is configured to substantially automatically purge excess fluid from the pumping chamber to an area external to the apparatus.

Methods and devices for preserving tissues

Methods and apparatus for preserving detached tissues, especially digits and limbs, which are detached as a result of traumatic amputation. By using the methods and apparatus, detached tissues can be preserved for greater lengths of time and are ultimately in a better condition for replantation surgery.

Modular sample store

A modular sample storeincluding a storage area; a service area; a transfer area; a motorized robot with a lifting device and at least one platform; and a controller. The sample store service area includes one integrally formed cubic vat module and the sample store storage area includes at least one integrally formed cubic vat module. Each one of the aforementioned vat modules includes an essentially horizontal vat floor and four joining vat walls that are connected to the vat floor and that are leaving an open vat space. The modular sample store also includes upper side walls and a cover plate to close the sample store. Each vat floor and vat wall includes an outside liner and an inside liner, which outside and inside liners in each case are separated by a clearance. This clearance is essentially filled with a polymer foam material that provides fixation of the outside and inside liners to each other as well as thermal insulation of and reinforcement to the thus integrally formed cubic vat module sandwich construction.

Organ care solution for ex-vivo machine perfusion of donor lungs

An ex-vivo lung solution for machine perfusion of donor lungs on OCS. The solution may be mixed with whole blood or packed red blood cells to form the OCS lung perfusion solution.

Biomaterial Freezing

The biocontainer of the present invention provides a low cost, simple solution of many of the problems encountered during shipping, freezing and thawing of biopharmaceutical materials. The present invention enables a user to monitor the temperature profile of each biopharmaceutical container during the cryogenic process, so as to ensure the integrity of materials within each biocontainer by using a pre-installed and pre-sterilized temperature sensor. In some embodiments, the sensor assembly includes a wireless transmitter and is capable of transmitting information regarding the measured reading. In other embodiments, the sensor assembly includes a processing unit, which determines whether the temperature profile is acceptable. In a further embodiment, an indicator is included, such that the processing unit may indicate whether the biopharmaceutical material has been properly frozen. In other embodiments, the sensor assembly also includes a storage element, which is capable of storing various parameters during the freezing process.

Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells

A method of preserving an umbilical cord is disclosed. The method comprises obtaining a segment of an umbilical cord; mincing the segment of the umbilical cord into cord tissue pieces; admixing the cord tissue pieces with a cryogenic composition comprising a cryoprotectant and a protein to form a mixture; shaking the mixture for a duration of no shorter than 20 minutes and no longer than 40 minutes; and cryopreserving the mixture.

Solution for non-programmed cell cryopreservation

The invention provides a solution for non-programmed cell cryopreservation, which comprises 1.0-28 w/v % of cell membrane protectant, 1.0-18 w/v % of permeable intracellular protectant, 3.0-28 w/v % of cell sedimentation stabilizer, and the balance of solvent. The cell cryopreservation solution provided by the invention is good for protecting cells. After the cryopreservation solution is added to cells, the cells can be cryopreserved in a refrigerator of −80 DEG C. directly without complicated programmed cryopreservation, thus, the time for cell cryopreservation is shortened greatly and the efficiency of cryopreservation is improved. Therefore, the cryopreservation solution is suitable for cryopreserving a large number of cells. The recovery rate of the cells cryopreserved is high, the growth and differentiation of the recovered cells is normal. The components of the cryopreservation solution are stable, thus the cryopreservation solution can be preserved with good property for a long time.

SYSTEMS AND METHODS FOR EX-VIVO ORGAN CARE AND FOR USING LACTATE AS AN INDICATION OF DONOR ORGAN STATUS

The invention provides, in various embodiments, systems, devices and methods relating to ex-vivo organ care. In certain embodiments, the invention relates to maintaining an organ ex-vivo at near-physiologic conditions. The present application describes a method for using lactate measurement in the arterial and the venous blood lines of the Organ Care System Heart perfusion device to evaluate the: 1) The overall perfusion status of an isolated heart and 2) The metabolic status of an isolated heart and 3) the overall vascular patency of an isolated donor heart. This aspect of the present invention uses the property of myocardial cell's unique ability to produce/generate lactate when they are starved for oxygen and metabolize/utilize lactate for energy production when they are well perfused with oxygen. 1. An organ care system configured to perfuse a heart , the system comprising:a chassis; a fluid conduit with a first interface configured to connect to an aorta of the heart and a second interface configured to connect to a pulmonary vein of the heart;', 'a Lactate A sensor configured to measure lactate in the first interface;', 'a Lactate V sensor configured to measure lactate in the second interface; and, 'an organ chamber assembly mounted to the chassis for containing the heart during perfusion, the organ chamber comprisinga processor configured to calculate a Lactate V−A differential using lactate values measured by the Lactate A sensor and the Lactate V sensor, wherein the Lactate V−A differential is calculated at two different times to correlate a change between the V−A lactate differentials over time with suitability of the heart for transplantation.2. The system of claim 1 , wherein the organ chamber assembly is disposable.3. The system of wherein the Lactate V−A differential is calculated at least once an hour.4. The system of claim 1 , comprising a flow select valve configured to control a flow of the perfusion fluid to the first and second interfaces.5. The ...

Method for preserving a whole mammalian organ

Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes. 1. A method of preserving a whole mammalian organ , comprising contacting the whole organ with a solution comprising (a) polymerized hemoglobin derived from mammalian blood and (b) cell culture medium.2. A method according to claim 1 , where the organ is a human liver claim 1 , a human lung claim 1 , or a human kidney. This application is a divisional of U.S. application Ser. No. 13/041, 685, filed Mar. 7, 2011, which is a continuation of U.S. application Ser. No. 11/626,727, filed Jan. 24, 2007, which claims the benefit of U.S. Provisional Application No. 60/761,663, filed on Jan. 24, 2006.The entire teachings of the above applications are incorporated herein by reference.The application relates to the field of cell biology. In particular, the application relates to solutions, suspensions, methods, and processes useful for the isolation, culture, and transplantation of cells and tissues.The transplantation of cells, tissues, and organs holds great promise for the treatment of many diseases. For example, pancreatic islet transplantation can reverse insulin-dependent diabetes. Unfortunately, the procedure is hampered by a short supply of islets and a gradual loss of islet function after transplantation. The inconsistency of islet isolation outcomes has been a major limitation to widespread clinical application of islet ...

Methods and apparatus for organ support

An organ support apparatus includes: (a) a fluid circuit defining upstream and downstream legs adapted to be connected to an organ to be supported; (b) a circulation pump connected to the fluid circuit for circulating a process fluid through the fluid circuit and the organ; and (c) a first waveform generator connected to the fluid circuit for impressing a preselected pressure waveform on the process fluid.

APPARATUS AND METHOD FOR MAINTAINING AND/OR RESTORING VIABILITY OF ORGANS

Methods of monitoring, maintaining, and/or restoring viability of at least one organ in at least one device selected from an organ transporter, perfusion apparatus, cassette, and organ diagnostic apparatus, the methods including monitoring data comprising information relating to events occurring while at least one organ is present in at least one of an organ transporter, perfusion apparatus, cassette, and/or organ diagnostic apparatus to form a data record; and connecting the at least one of the organ transporter, perfusion apparatus, cassette, and/or organ diagnostic apparatus to a network through wiring or wirelessly, and uploading the data record to a database. 1. A method of monitoring , maintaining , and/or restoring viability of at least one organ in at least one device selected from an organ transporter , perfusion apparatus , cassette , and organ diagnostic apparatus , the method comprising:monitoring data comprising information relating to events occurring while at least one organ is present in at least one of an organ transporter, perfusion apparatus, cassette, and/or organ diagnostic apparatus to form a data record; andconnecting the at least one of the organ transporter, perfusion apparatus, cassette, and/or organ diagnostic apparatus to a network through wiring or wirelessly, and uploading the data record to a database.2. A method of transporting and/or storing at least one organ in at least one device selected from an organ transporter , perfusion apparatus , cassette , and/or organ diagnostic apparatus , the method comprising: 'information relating to events occurring while at least one same or different organ was transported and/or stored in a least one same or different device, wherein the information is cross-referenced to outcome data relating to outcomes of transplantation of the at least one same or different organ that was transported and/or stored.', 'adjusting transport and/or storage parameters of at least one device for the transport and/or ...

Devices and Methods for Processing a Biomaterial in a Closed System

Disclosed herein are methods and devices for processing a biomaterial in a closed system and administering the processed biomaterial to a subject.

Freeze-Dried Plasma Formats for the Trauma Care Field

Disclosed are freeze-dried plasma formats specifically designed for the trauma care field. Blood plasma is subjected to a glucose removal step, a protein fraction up-concentration step and addition of stabilizers prior to freeze-drying. Preferable stabilizers are glutamine dipeptides, glutamine and glycine. The glutamine based formulation is added direct to plasma and serves three main purposes: 1) Increases stability of plasma proteins and stabilizes pH in freeze-dried state; 2) Increases stability of plasma proteins against Gamma Irradiation and thus allows for the application of a terminal sterilization step; 3) Introduces supplements beneficial to the trauma patient. 130.-. (canceled)31. A method of increasing coagulation faetor stability of plasma comprising:treating the plasma to reduce glucose concentration; andfreeze-drying the treated plasma.32. The method of claim 31 , wherein treating comprises passing the plasma through a filtration system that removes glucose.33. The method of claim 32 , wherein the filtration system is a hollow fiber filtration system.34. The method of claim 31 , wherein plasma glucose concentration is reduced by at least about 75 percent.35. The method of claim 31 , wherein treating comprises collecting said plasma with glucose-free anti-coagulants.36. The method of claim 31 , further comprising supplementing the plasma with a stabilizer.37. The method of claim 36 , wherein the stabilizer is a glutamine-containing dipeptide claim 36 ,38. The method of claim 31 , further comprising sterilizing the freeze-dried and treated plasma with gamma irradiation and heat.39. The freeze-dried plasma made by the method of .40. The method of claim 31 , further comprising reconstituting the freeze-dried plasma with an oxygen-free rehydration medium.41. A plasma made by the method of .42. The plasma of claim 41 , which is supplemented with gas which is beneficial to a trauma patient or depleted of a gas that is harmful to said trauma patient.43. The ...

Method For The Analysis of Biological Samples Through Medical Ultrasound

A method for the conservation of human and animal anatomical parts, both normal and pathological, which comprises a hydration phase, immersion phase and packing phase. The hydration phase comprises immersing the anatomical part in and preserving and hydrating substance. The Immersion and Packing phases comprise immersing the specimen in a gel substance contained in a polyurethane, gel latex or silicone container that allows its analysis and study by ultrasound. 1. A method of preserving an anatomical specimen comprising the steps of:a. Hydrating the specimen in a moisturizing solution comprising a preservative;b. Immersing the specimen in a preservative gel; andc. Placing the specimen in an airtight container that is substantially invisible to ultrasound analysis2. The method of claim 1 , wherein the moisturizing solution comprises about 0.9% saline claim 1 , absolute alcohol and glycerin.3. The method of claim 2 , wherein the moisturizing solution comprises:a. about 200 cc 0.9% saline solution;b. about 100 cc absolute alcohol; andc. about 200 cc glycerin.4. The method of claim 2 , wherein the moisturizing solution further comprises at least one of formaldehyde claim 2 , bromide dimethyl benzyl ammonium lauryl or a combination thereof.5. The method of claim 4 , wherein the moisturizing solution comprises claim 4 , per 500 g of specimen:a. about 500 cc of 0.9% saline solution;b. about 200 cc of glycerin;c. about 20 cc of formaldehyde; andd. about 200 cc of absolute alcohol.6. The method of claim 4 , wherein the moisturizing solution comprises claim 4 , per 500 g of specimen:a. about 200 cc of 0.9% saline solution;b. about 100 cc of glycerin;c. about 20 cc of formaldehyde; andd. about 200 cc of absolute alcohol.7. The method of claim 1 , wherein the preservative gel comprises;a. Ultrasound gel;b. Formalin;c. Absolute Alcohol;d. Glycerin; ande. Carbapol.8. The method of claim 7 , wherein the preservative gel comprises claim 7 , per 500 g of specimen:a. about 1 gallon ...

COMPOSITION FOR THE COLD STORAGE OF ORGANS

The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and/or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods. 1. Cold organ preservation composition that comprises , jointly or separately ,(i) cardiotrophin-1 or a functionally equivalent variant thereof and(ii) a cold organ preservation solution.2. The composition according to claim 1 , wherein the cold organ preservation solution comprises(a) at least one buffer agent(b) at least one impermeating agent and(c) at least one electrolyte.3. The composition according to claim 2 , wherein the buffer agent is selected from the group consisting of phosphate claim 2 , bicarbonate claim 2 , sulfate claim 2 , histidine claim 2 , histidine-HCl claim 2 , HEPES claim 2 , citrate and a combination thereof; the impermeating agent is selected from the group formed by histidine claim 2 , glucose claim 2 , sucrose claim 2 , mannitol claim 2 , trehalose claim 2 , gluconate claim 2 , citrate claim 2 , lactobionate claim 2 , raffinose and a combination thereof; and/or the electrolyte is selected from the group formed by sodium claim 2 , potassium claim 2 , magnesium claim 2 , calcium claim 2 , chloride and a combination thereof.4. (canceled)5. The composition according to claim 1 , wherein the cold organ preservation solution additionally comprises at least one colloid agent claim 1 , at least one metabolic agent claim 1 , at least one amino acid claim 1 , at least one antioxidant agent claim 1 , at least one vitamin and/or at least one antibiotic.6. (canceled)7. The composition according to claim 5 , wherein the colloid agent is selected ...

SYSTEM FOR COLLECTING AND PRESERVING TISSUE CORES

A cooling system for preserving tissue is disclosed. The cooling system comprises a base member, a temperature control sleeve constructed of a thermally conductive material, and a selectively removable lid member. The base member defines a reservoir and receives the temperature control sleeve. The temperature control sleeve at least partially defines a tissue collector chamber that is configured to receive a tissue collector. The temperature control sleeve is in communication with the reservoir. The reservoir is configured to receive a cooling medium. A slit formed within the tissue collection chamber that is sized to receive a tubing connected to the tissue collector therethrough. The lid member is configured to be selectively attached to the base member, and permit access to a tube mount for the tissue collector when the lid is attached to the base member. 1. A temperature controlled system , comprising:a base member defining a reservoir that is configured to receive a temperature controlled medium;a temperature control sleeve constructed of a thermally conductive material, wherein the temperature control sleeve at least partially defines a tissue collector chamber; and wherein the temperature control sleeve is in communication with the reservoir;a slit formed within the tissue collector chamber that is sized to receive a tubing connected to the tissue collector therethrough; anda lid member that is configured to be selectively attached to the base member, where in the lid member permits access to a tube mount for the tissue collector, when the lid is attached to the base member.2. The temperature controlled system of claim 1 , wherein the slit extends the longitudinal extent of the tissue collector chamber.3. The temperature controlled system of claim 1 , further comprising a channel disposed within the base member claim 1 , wherein the channel is in communication with an interior of the temperature control sleeve through the slit claim 1 , and wherein the ...

Micromanipulation and Storage Apparatus and Methods

An apparatus for micromanipulation of biological material, includes a vessel () having a reservoir () wherein the vessel has a channel () formed in a portion of the reservoir, the channel including an intermediate restriction () dimensioned to resist passage of the biological material but allow passage of liquid treatment solutions. 1. An apparatus for micromanipulation of at least one biological material , said apparatus including a vessel having a reservoir wherein said vessel has a channel formed in a portion of said reservoir , said channel including an intermediate restriction dimensioned to resist passage of said biological material but allow passage of liquid treatment solutions.2. An apparatus according to claim 1 , wherein said intermediate restriction includes one of:a physical narrowing of the passage,an orifice partially blocking the channel,at least one divot, anda combination of any of above.3. An apparatus according to claim 2 , wherein said vessel includes an open top with said channel formed at a bottom of the vessel.4. An apparatus according to claim 3 , wherein said channel includes sub-reservoirs at either end of said restriction.5. An apparatus according to claim 4 , wherein said vessel is formed of a highly thermal diffusivity material.6. An apparatus according to claim 5 , wherein said vessel optimises heat transfer in the region of said sub-reservoirs and channel.7. An apparatus according to claim 3 , including one of a cap and lid adapted to seal the open top of said vessel.8. An apparatus according to claim 6 , including a portion adapted to receive at least one of a bar-code and other indicia.10. An apparatus according to claim 1 , being a semi-automatable device including provision for at least one said vessel and including an arrangement to irrigate said captive biological material with:at least one of pre-vitrification and vitrification solutions andfluidics to prepare said captive material for vitrification.11. A method of ...

Method of cryopreserving selected sperm cells

The present invention provides a method of cryopreserving sperm that have been selected for a specific characteristic. In a preferred embodiment, the method is employed to freeze sex-selected sperm. Although the cryopreservation method of the invention can be used to freeze sperm selected by any number of selection methods, selection using flow cytometry is preferred. The present invention also provides a frozen sperm sample that has been selected for a particular characteristic, such as sex-type. In preferred embodiments, the frozen sperm sample includes mammalian sperm, such as, for example, human, bovine, equine, porcine, ovine, elk, or bison sperm. The frozen selected sperm sample can be used in a variety of applications. In particular, the sample can be thawed and used for fertilization. Accordingly, the invention also includes a method of using the frozen selected sperm sample for artificial insemination or in vitro fertilization.

MICROTOME AND CRYOSTAT

Provided is a microtome in which refrigerant piping and electrical wiring are not impeditive so that cleaning and other works can be surely conducted. 1. A microtome comprising:a cutting blade attached to a blade holder;a head which holds a sample so that a front face side of the sample faces the cutting blade;an alignment mechanism which is provided on a back face side of the head and aligns said head so that the head is rotatable in a vertical direction and is rotatable in a horizontal direction perpendicular to the vertical direction;a body portion which is provided on a back face side of the alignment mechanism and has a contact separation mechanism allowing the head to contact with and separate from the cutting blade;a cylindrical coupling portion which has a hollow portion formed in its center and couples the body portion with the head;a temperature controller provided in the head for cooling or heating the sample held by the head; andrefrigerant piping for circulating a refrigerant in the temperature controller, and electrical wiring for the temperature controller, wherein:said alignment mechanism includes a spherical member coupled with the back face side of the head and having a spherical outer periphery, and a retainer portion for slidably retaining the outer periphery of the spherical member along the spherical surface;in said spherical member, a through hole communicating with the hollow portion of said coupling portion is formed; andsaid refrigerant piping and electrical wiring are connected with the temperature controller in the head through the through hole of the spherical member and the hollow portion of the coupling portion.2. The microtome according to claim 1 , wherein:an inner wall surface on a rear face side of said spherical member is spherically formed;a ring-shaped member is provided in which its outer periphery is spherically formed so as to be slidable in contact with the inner wall surface of the spherical member and a second through hole ...

BLOOD PLASMA LYOPHILIZATION PROCESS

The present invention relates to a lyophilized plasma, resulting from a mixture of plasmas originating from selected donors, which is virally attenuated and compatible with all blood groups and to the process for obtaining same. 2. The process as claimed in claim 1 , characterized in that said donor individuals belong to blood group AB.3. The process as claimed in claim 1 , characterized in that at least one of said donor individuals belongs to blood group A and that at least one of said donor individuals belongs to blood group B and in that the volume of plasma obtained from the donor individual(s) belonging to blood group A is identical to the volume of plasma obtained from the donor individual(s) belonging to blood group B.4. The process as claimed in claim 1 , characterized in that unit plasmas constituting the mixture of plasmas of step b) are free of hemolyzing antibody.5. The process as claimed in claim 1 , characterized in that the unit plasmas constituting the mixture of plasmas of step b) have an agglutinin titer of less than 64.6. The process claimed in claim 1 , characterized in that the unit plasmas constituting the mixture of plasmas of step b) are attenuated via the action of a photochemical agent chosen from amotosalen claim 1 , methylene blue and riboflavin.7. The process as claimed in claim 1 , characterized in that the unit plasmas constituting the mixture of plasmas of step b) are attenuated by the action of amotosalen.8. The process as claimed in claim 1 , characterized in that the lyophilizing step c) makes it possible to obtain a lyophilized plasma which has a moisture content of less than 2%.9. A process for preparing reconstituted plasma comprising the step of reconstituting the plasma obtained by means of the process as defined in in a take-up solvent for injection.10. A lyophilized plasma which is compatible with all blood groups claim 1 , characterized in that it comprises a mixture of plasmas collected from donor individuals claim 1 , at ...

TRANSPLANTS

The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. 17-. (canceled)8. A method of reducing injury to vasculature that has been explanted or implanted by administering to the vasculature ex vivo a composition including:(i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and(ii) an antiarrhythmic agent.9. A method according to claim 10 , wherein the composition further includes at least one muscle relaxant.10. A method according to claim 11 , wherein the muscle relaxant is selected from the group consisting of a botulinum toxin claim 11 , myosin light chain kinase inhibitor claim 11 , calmodulin blocker claim 11 , calcium channel blocker claim 11 , nitric oxide donor claim 11 , dipyridamole claim 11 , beta blocker claim 11 , Na/H inhibitor claim 11 , high magnesium claim 11 , opioid claim 11 , phosphodiesterase inhibitors claim 11 , alpha-adrenergic receptor antagonists and Rho kinase inhibitors.11. A method according to claim 12 , wherein the phosphodiesterase inhibitor is selected from the group consisting of papaverine claim 12 , milrinone claim 12 , theophylline and dipyridamole.12. A method according to claim 12 , wherein the alpha-adrenergic receptor antagonist is phenoxybenzamine.13. A method according to claim 12 , wherein the Rho kinase inhibitor is selected from the group consisting of HA1077 and fausdil.14. A method according to claim 10 , wherein the composition is pre-mixed with the patient's blood.15. A method according to claim 10 , wherein ...

Methods for sorting particles

A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles.

System and method for sorting cells

Improved flow cytometer system particularly adapted to use for sex-selected sperm sorting include enhanced sheath fluid and other strategies which minimize stress on the sperm cells, including a 2.9 percent sodium citrate sheath solution for bovine species and a hepes bovine gamete media for equine species. Improved collection systems and techniques for the process are described so that commercial applications of sperms samples as well as the resulting animals may be achieved.

SYSTEMS AND METHODS FOR EX VIVO LUNG CARE

Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to rebreath a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to reoxygenate the perfusion fluid by ventilating the lung with an oxygenation gas. 1. A method of preserving a lung ex vivo comprising:circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface;ventilating the lung through a tracheal interface by flowing a captive volume of a ventilation gas back and forth between the lung and a variable volume chamber; andintroducing into the captive volume an additional flow of the ventilation gas and venting excess ventilation gas from the captive volume to maintain a predetermined composition of the ventilation gas and to maintain a minimum gas pressure of the captive volume.2. The method of claim 1 , wherein the ventilation gas includes a composition of oxygen claim 1 , carbon dioxide and an inert gas.3. The method of claim 2 , wherein the inert gas is nitrogen.4. The method of claim 1 , wherein a gas content of the perfusion fluid reaches an equilibrium level corresponding to the predetermined composition of the ventilation gas.5. The method of claim 1 , wherein the predetermined composition of the ventilation gas includes about 5-20% oxygen and about 2-10% carbon dioxide.6. The method of claim 5 ...

System, Method, and Device For Preserving Blood or its Components in Gas Medium Under Pressure

A system, method, and device for preserving blood and its components is described. The system and method generally include a device having a body defining a chamber, the chamber being configured to receive at least one bag containing blood or its components, the at least one bag being permeable to gas, for example, xenon. A cover is hermetically sealable to the body. An inlet is in fluid communication with the chamber. A pressure indicator is configured to indicate pressure in the chamber, the pressure indicator including a conduit containing a liquid. A portion of the conduit is transparent such that the liquid is visible. A source of pressurized gas, such as xenon, is provided to provide the pressurized gas to the chamber. 1. A method of preserving blood and its components , comprising: a body defining a chamber;', 'a cover hermetically sealable to the body;', 'an inlet configured to provide pressurized xenon gas to the chamber from a xenon gas source; and', 'a pressure indicator configured to indicate pressure in the chamber, the pressure indicator including a conduit containing a liquid;', 'wherein a portion of the conduit is transparent such that the liquid is visible;, 'providing a device, includingplacing at least one bag containing blood or its components disposed in the chamber, the at least one bag being permeable to xenon gas;hermetically sealing the chamber;supplying the chamber with xenon gas from the xenon gas source such that the xenon gas saturates the blood or its components.2. The method of claim 1 , wherein the xenon gas has a xenon content of no less than 65%.3. The method of claim 2 , wherein the xenon gas is supplied to the chamber until the pressure in the chamber reaches approximately 3.5 bars-5 bars.4. The method of claim 3 , further comprising placing the device in a refrigerator at a temperature of between 3° C.-6° C. after the chamber is supplied with approximately 3.5 bars-5 bars of pressure.5. The method of claim 1 , further comprising ...

METHOD FOR CRYOPRESERVATION OF HUMAN SPERMATOZOA FREE FROM SEMINAL PLASMA USING A FAST AND SIMPLE ASEPTIC VITRIFICATION-DEVITRIFICATION PROCESS; PORTABLE KIT FOR CARRYING OUT THE METHOD; AND USE OF THE SAME FOR TREATMENT OF DISORDERS RELATED TO REPRODUCTIVE FAILURES

The present invention discloses a method for cryopreservation of human spermatozoa: the method comprises providing spermatozoa free from seminal liquid; mixing the spermatozoa with vitrification medium, wherein the main cryoprotectant agent is 0.1-0.3 M sucrose; placing the sample inside straws and rapidly freezing them; refrigerating the straws with no need of liquid N; and devitrifying the sample in a medium of the present invention. The present invention furthermore discloses a portable kit that makes easy to implement the method, said kit comprising vitrification and devitrification solutions in the volumes required to develop the method and the physical support to carry out the same, i.e. the straws. The use of this kit is also disclosed for the treatment of disorders related to reproductive failures. 1. Method for cryopreservation of human spermatozoa free from seminal plasma using a fast and simple aseptic vitrification-devitrification process , wherein said method comprises:(a) providing spermatozoa free from seminal liquid; i) buffering medium for spermatozoa,', 'ii) a cryoprotectant, and', 'iii) a dextran supplemented serum;, '(b) resuspending and mixing the spermatozoa obtained in step (a) in a 1:1 volumetric ratio with a vitrification medium comprising{'sup': 6', '6, '(c) mixing and adjusting the final concentration of spermatozoa within a range from 0.2×10to 1.8×10spermatozoa per 100 μl of vitrification medium;'}(d) placing 100 μl of the mixture of spermatozoa and vitrification medium immediately after step (c) in a 0.25 ml receptacle or straw, then placing this straw inside other 0.5 ml straw to be sealed;{'sub': '2', '(e) immersing the 0.5 ml straw with the sperm content in horizontal position in liquid Nfor no more than 5 seconds;'}(f) keeping the sperm sample inside the straws at a temperature lower than −75° C.; i) buffering medium for spermatozoa,', 'ii) HTF supplemented with 1% w/v BSA, and', 'iii) a substituting serum supplemented with dextran, ...

PLATFORM FOR ENGINEERED IMPLANTABLE TISSUES AND ORGANS AND METHODS OF MAKING THE SAME

Disclosed are engineered tissues and organs comprising one or more muscle cell-containing layers, the engineered tissue or organ consisting essentially of cellular material, provided that the engineered tissue or organ is implantable in a vertebrate subject and not a vascular tube. 1. A living , three-dimensional engineered tissue or organ comprising one or more layers , the one or more layers characterized by one or more of: a) substantially scaffold-free at the time of use; and b) bioprinted , the one or more layers suitable for implantation in a vertebrate subject upon sufficient maturation; provided that at least one layer of the engineered tissue or organ comprises muscle cells and that the engineered tissue or organ is not a vascular tube.2. The tissue or organ of claim 1 , wherein at least one layer comprises a plurality of cell types claim 1 , the cell types spatially arranged relative to each other to create a planar geometry.3. The tissue or organ of claim 2 , wherein at least one layer is at least 100 μm thick in its smallest dimension at the time of fabrication.4. The tissue or organ of claim 1 , comprising a plurality of layers claim 1 , at least one layer compositionally or architecturally distinct from at least one other layer to create a laminar geometry.5. The tissue or organ of claim 4 , wherein at least one layer is at least 100 μm thick in its smallest dimension at the time of fabrication.6. The tissue or organ of claim 1 , wherein the tissue or organ is a sac claim 1 , sheet claim 1 , or tube claim 1 , wherein said tube is not a vascular tube.7. The tissue or organ of claim 1 , wherein the tissue or organ is substantially free of any pre-formed scaffold at the time of use.8. The tissue or organ of claim 1 , wherein the tissue or organ is bioprinted.9. The tissue or organ of claim 1 , wherein the one or more layers generates an extracellular matrix.10. The tissue or organ of claim 1 , wherein the muscle cells are smooth muscle cells.11. The ...

INORGANIC PYROPHOSPHATE AND USES THEREOF

The present invention provides a new and improved sperm stimulating additive comprising a certain amount of inorganic pyrophosphate (PPi). Addition of PPi in the media for human/animal in vitro fertilization (IVF) improves fertilization rate; addition of PPi in the semen extender for farm animal artificial insemination (AI) may improve pregnancy rates; furthermore, mammalian oocytes matured in vitro in a medium including PPi attain improved fertilization and developmental potential, while embryos cultured in medium supplemented with PPi have improved development to blastocyst. 1. A sperm preservation media comprising inorganic pyrophosphate (PPi).2. The sperm preservation media of claim 1 , wherein the concentration of PPi is between about 1 μM and about 200 μM.3. The sperm preservation media of claim 1 , wherein the concentration of PPi is between about 1 μM and about 20 μM.4. The sperm preservation media of claim 1 , wherein the concentration of PPi is about 10 μM.5. The sperm preservation media of claim 1 , wherein said preservation media is used to preserve sperm from a porcine.6. A media for sperm processing comprising inorganic pyrophosphate (PPi).7. The media of claim 6 , wherein the concentration of PPi is between about 1 μM and about 200 μM.8. The media of claim 6 , wherein the concentration of PPi is between about 1 μM and about 20 μM.9. A media for in vitro fertilization (IVF) or artificial insemination (AI) comprising inorganic pyrophosphate (PPi).10. The media of claim 9 , wherein the concentration of PPi is between about 1 μM and about 200 μM.11. The media of claim 9 , wherein the concentration of PPi is between about 1 μM and about 20 μM.12. A semen sexing method claim 9 , comprising:(a) separating a mixed sperm suspension in a first culture medium into a population of x-bearing or y-bearing sperm with the aid of an elutant medium;(b) preserving the x-bearing or y-bearing sperm in a second culture medium,wherein, inorganic pyrophosphate (PPi) is added ...

DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide. 121.-. (canceled)24. The compound according to claim 22 , wherein R represents a CHORgroup; Rand Rrepresent claim 22 , independently from one another claim 22 , an ORgroup; and Rrepresents an ORor NRC(O)Rgroup.25. The compound according to claim 22 , wherein Rrepresents a hydrogen atom or an ORgroup.26. The compound according to claim 22 , wherein Y represents a NRRor CHNRRgroup.27. The compound according to claim 22 , wherein Rrepresents an ORgroup.28. The compound according to claim 22 , wherein Y represents a NRRor CHNRRgroup and Rrepresents an ORgroup claim 22 , with:{'sub': 6', '7', '49, 'Rand Rrepresenting each a hydrogen atom and Rrepresenting an O-protecting group, or'}{'sub': 49', '6', '7, 'Rand Rrepresenting each a hydrogen atom and Rrepresenting a N-protecting group.'}32. A peptide (VI) wherein at least one amino acid has been replaced with a compound of formula (I) according to wherein Y═NHRor CHNHRand/or R═OH claim 22 , the Y and/or Rgroup being linked to an amino acid of the peptide by a peptide bond.34. A pharmaceutical or cosmetic composition comprising at least one peptide (VI) according to and a pharmaceutically acceptable carrier.35. The compound according to claim 24 , wherein R claim 24 , Rand Rrepresent a hydrogen atom or an O-protecting group claim 24 , Rrepresents a hydrogen atom and Rrepresents a (C-C)alkyl group.36. The compound according to claim 25 , wherein Rrepresents a hydrogen atom or an O-protecting group37. The compound according to claim 26 , wherein Rrepresents a hydrogen atom or a (C-C)alkyl group and Rrepresents:a hydrogen atom,{'sub': 1', '6', '1', '6, ' ...

Flush preservation solution

Flush preservation solution for the preservation of cells in the absence of a blood supply comprising: 149.-. (canceled)51. The flush preservation solution of claim 50 , comprising:iv) at least one component with calcium transport blocking properties and optionally additionally a component with an anti-calcium action activity.52. The flush preservation solution of claim 50 , wherein the calcium transport blocker is selected from the group consisting of nicardipine claim 50 , diltiazem claim 50 , verapamil claim 50 , nisoldipine claim 50 , chlorpromazine and trifluorperazine.53. The flush preservation solution of claim 50 , wherein the pH buffer is selected from the group consisting of a sodium phosphate buffer claim 50 , a potassium phosphate buffer claim 50 , and combinations thereof.54. The flush preservation solution of claim 50 , which additionally comprises:xiv) at least one component that acts reversibly upon crossbridge function in muscle.55. Flush preservation solution for heart preservation which comprises a combination of component classes given below of specific type listed{'sub': 2', '4, 'iii) NaHPO'}{'sub': 2', '4', '2, 'iii) NaHPO.2HO'}{'sub': 2', '4, 'iii) KHPO'}ii) Sucrose{'sub': '2', 'viii) MgCl'}{'sub': '2', 'viii) CaCl'}viii) NaCliv) Diltiazem57. A method for the preparation of a flush preservation solution as claimed in claim 50 , comprising adding components under pharmaceutically acceptable conditions in sequence to water claim 50 , and unstable components if any claim 50 , and dissolving claim 50 , adding any unstable components and making the solution nearly up to volume and finally making up to volume to regulate pH claim 50 , sterilising and cooling.58. The flush preservation solution of claim 50 , wherein said component with an anti-calcium action activity comprises a calcium chelator.59. The flush preservation solution of wherein component (ii) is present in an amount in the range 50-150 mmol/l claim 50 , each component (iii) is present ...

EXTRACORPOREAL PERFUSION CIRCUIT SENSOR ASSEMBLY AND METHODS OF ISOLATING SENSORS THEREOF IN SEPARATE DRY AND WET ENVIRONMENTS AND STERILIZATION OF THE ASSEMBLY

Packaged cardiopulmonary bypass or organ perfusion system sensor subassemblies are provided. The packaged sensor subassemblies include a sensor subassembly and a package. The sensor subassembly includes a pre-calibrated pH sensor in a dry environment, a pre-calibrated PC0sensor in a dry environment, and a pre-calibrated pC0sensor in a wet environment, is sterile, and is disposed in the package. Also provided are methods of use of the packaged cardiopulmonary bypass or organ perfusion system sensor subassemblies. 1. A packaged cardiopulmonary bypass or organ perfusion system sensor subassembly comprising:a sensor subassembly, anda package;{'sub': 2', '2, 'wherein the sensor subassembly comprises a pre-calibrated pH sensor in a dry environment, a pre-calibrated pOsensor in a dry environment, and a pre-calibrated pCOsensor in a wet environment; is sterile; and is disposed in the package.'}2. A packaged sensor subassembly according to claim 1 , wherein the pH sensor claim 1 , the pOsensor claim 1 , and the pCOsensor do not require further calibration before use in cardiopulmonary bypass or isolated organ perfusion.3. A packaged sensor subassembly according to claim 1 , wherein the pH sensor claim 1 , the pOsensor claim 1 , and the pCOsensor are factory pre-calibrated.4. A packaged sensor subassembly according to claim 1 , wherein the sensors are connected in series.5. A packaged sensor subassembly according to claim 1 , wherein:the sensor subassembly further comprises a conduit with a bidirectional flow passage, an inlet/outlet end, an outlet/inlet end, two valves, a closed and sealed chamber, and a liquid buffer solution; and{'sub': '2', 'the conduit extends between the inlet/outlet end and the outlet/inlet end, the two valves are disposed along the conduit, the closed and sealed chamber is disposed between the two valves, the liquid buffer solution is in the closed and sealed chamber, and the pCOsensor is maintained in the liquid buffer solution.'}6. A packaged sensor ...

Method of Treating Organs

A method of treating tissue, including organs, with electromagnetic energy to decrease the fat content of the tissue comprises the steps of providing a source of electromagnetic energy, and subjecting adipose cells to the source of electromagnetic energy at hypothermic conditions. The tissue may be harvested and in an isolated state, such as being placed in an organ preservation system. Electromagnetic energy between 600 nm to 700 nm is used for treatment. During treatment, target tissue such as a harvested organ is subject to perfusion. 1. A method of decreasing fat content on a harvested organ comprising the steps of:subjecting cells of the harvested organ to electromagnetic energy at hypothermic conditions, said electromagnetic energy provided by at least one source.2. The method of wherein the cells comprise adipose cells on the surface of the harvested organ.3. The method of wherein the source is disposed at a pre-determined distance from the organ.4. The method of wherein the electromagnetic energy has a wavelength between 600 nm to 700 nm.5. The method of wherein the source is a laser.6. The method of wherein the source is a light emitting diode.7. The method of wherein the electromagnetic energy is provided by an array of lasers.8. The method of wherein the electromagnetic energy is provided by an array of light emitting diodes.9. The method of wherein the electromagnetic energy is provided by a combination of at least one laser and at least one light emitting diode.10. The method of wherein the cells comprise adipose cells claim 1 , and the step of subjecting cells to electromagnetic energy comprises the step of:disposing the source in contact with adipose tissue for a pre-determined period of time.11. The method of wherein the step of disposing the source in contact comprises the step of:positioning one or more sources of electromagnetic energy into a desired orientation.12. The method of wherein one or more sources comprise at least a light emitting diode ...

APPARATUS AND METHOD FOR MAINTAINING AND/OR RESTORING VIABILITY OF ORGANS

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. The method includes perfusing the organ at hypothermic and/or normothermic temperatures. The methods further include perfusing the organ at hypothermic and/or normothermic temperatures with a second perfusate containing a substance for reacting with the organ. Condition of the organ may be automatically monitored, and the perfusion process can be automatically controlled using a control program. 1. A method for perfusing an organ , comprising:supplying a first medical fluid to a portable housing;supplying a second medical fluid to the portable housing; andplacing an organ on an organ supporting surface within the portable housing, wherein the organ is in fluid contact with the first medical fluid and the second medical fluid, and perfusing the organ with at least one of the first medical fluid and the second medical fluid.2. The method according to claim 1 , further comprising supplying substantially equal amounts of the first and second medical fluids to the portable housing.3. The method according to claim 1 , further comprising:establishing a fluid interface of the first and second medical fluids; andplacing the organ at the fluid interface.4. The method according to claim 1 , further comprising establishing the fluid interface at approximately a middle portion of the organ.5. The method according to claim 1 , wherein the first and second medical fluids do not mix.6. The method according to claim 1 , wherein the organ is a pancreas. This application is a divisional of U.S. patent application Ser. No. 12/379,239, filed Feb. 17, 2009, which is a division of U.S. patent application Ser. No. 11/075,690, filed Mar. 10, 2005, now U.S. Pat. No. 7,504,201, issued Mar. 17, 2009, the entire contents of which are hereby incorporated by ...

Composition for maintaining function of platelets

A composition for maintaining a function of platelets, the composition comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: wherein X represents a phenylene group; Y represents any one of a hydrogen atom and —(CH 2 ) m R 1 ; wherein m represents an integer of any one of 0 to 4; and R 1 is any one of —NR 5 COR 2 , —NR 5 SO 2 R 2 , and —NR 3 R 4 ; wherein R 2 represents any one of a C1 to C6 alkyl group, an aryl group, a C1 to C6 alkoxy group, and the like; R 3 and R 4 represent a C1 to C6 alkyl group or the like; and R 5 represents any one of a hydrogen atom, a C1 to C6 alkyl group, and the like; and Z represents any one of a hydrogen atom and a C1 to C6 alkyl group.

Compositions and methods for modulating ischemic injury

The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents. 1. A method for modulating ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising Inflammatory Response Modulating Cells (IRMCs) , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.2. A method for reducing ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.3. A method for increasing the time to ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.43. The method of any one of , , or wherein the IRMCs are selected from the group consisting of extraembryonic (EE) cells , extraembryonic HLA-G positive (EHP cells) , Amnion-derived Multipotent Progenitor (AMP) cells , Mesenchymal Stem Cells (MSC) , Sertoli cells , hepatic stellate cells , adult basal fibroblasts , donor matched unseparated bone marrow cells , donor ...

COAGULATION CONTROLLING AGENTS AND DEVICES COMPRISING THE SAME

A device and kit and method for controlling coagulation in a blood sample. The coagulation controlling agent is at least one of citrate, a protamine salt, its homologs and derivatives, benzamidine, or para-aminobenzamidine. Additives such as water soluble polymers and sugars are also contemplated. The device and kit comprise a container that contains an effective amount of thrombin and a coagulation controlling agent. The method combines thrombin and a coagulation controlling agent to stabilize thrombin or accelerate its activity in a blood sample. 1. A container for collecting serum , comprising a first end and a second end and at least one interior wall defining a reservoir portion for receiving the blood , wherein said reservoir comprises thrombin and at least one coagulation controlling agent , and a closure.2. The container of claim 1 , wherein said coagulation controlling agent is a polycarboxylic acid compound having a molecular weight of less than about 500 g/mol.3. The container of claim 2 , wherein said polycarboxylic acid compound is selected from the group consisting of citrate or isocitrate.4. The container of claim 2 , wherein a concentration of said coagulation controlling agent ranges from about 0.5 mM to about 100 mM of concentrated formulation.5. The container of claim 4 , wherein a concentration of said coagulation controlling agent ranges from about 1 mM to about 50 mM of concentrated formulation.6. The container of claim 1 , wherein said coagulation controlling agent is a protamine salt or a homolog or derivative thereof.7. The container of claim 6 , wherein a concentration of said coagulation controlling agent ranges from about 0.05 mg/mL to about 5 mg/mL of blood sample.8. The container of claim 7 , wherein a concentration of said coagulation controlling agent ranges from about 0.25 mg/mL to about 0.5 mg/mL of blood sample.9. The container of claim 1 , wherein said coagulation controlling agent is a weak competitive inhibitor of thrombin ...

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals. 1. A method of treating sperm cells during processing to improve cell integrity comprising the steps of:a. providing a sperm cell sample;b. processing the sperm cell sample; andc. adding one or more OSRs in the concentration range of 0.01 mg/ml to 5 mg/ml to the sperm cell sample to form a sperm cell composition.2. The method as claimed in claim 1 , further comprising the step of holding the sperm cell composition at a holding temperature without freezing for a period of time in the range of about 2 seconds to about a week following addition of the one or more OSRs.3. The method as claimed in claim 2 , wherein the holding period is selected from a range selected from the group of: about 2 sec to about 3 min; about 3 min to about 15 min; about 15 min to about 1 hr; about 1 hr to about 8 hrs; about 8 hrs to about 12 hrs; about 12 hrs to about 18 hrs; about 8 hrs to about 24 hrs; about 24 hrs to about 48 hrs; about 48 hrs to about 72 hrs;about 72 hrs to about 96 hrs; about 96 hrs to about 120 hrs; about 120 hrs to about 144 hrs; ...

ORGAN ARREST, PROTECTION AND PRESERVATION

The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. 117-. (canceled)18. A composition comprising:a pharmaceutically acceptable carrier;a compound chosen from the group consisting of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; anda local anesthetic;wherein the compound and the local anesthetic are present in the composition in an amount sufficient to arrest an organ.19. The composition of claim 18 , wherein the potassium channel opener or potassium channel agonist is selected from the group consisting of nicorandil claim 18 , diazoxide claim 18 , minoxidil claim 18 , pinicadil claim 18 , aprikalim claim 18 , cromokulim claim 18 , NS-1619 (1 claim 18 ,3-dihydro-1-[2-hydroxy5(trifluoromethyl) phenyl]5-(trifluoromethyl)2-H-benimidazol-one) claim 18 , amlodipine claim 18 , Bay K 8644(L-type)(1 claim 18 ,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)) claim 18 , bepridil HCl (L-type) claim 18 , calciseptine (L-type) claim 18 , omega-conotoxin GVIA (N-type) claim 18 , omega-conotoxin MVIIC (Q-type) claim 18 , cyproheptadine HCl claim 18 , dantrolene sodium (Ca release inhibitor) claim 18 , diltiazem HCl (L-type) claim 18 , filodipine claim 18 , flunarizine HCl (Ca/Na) claim 18 , fluspirilene (L-type) claim 18 , HA-1077 2HCl(1-(5 isoquinolinyl sulphonyl) homo piperazine.HCl) claim 18 , isradipine claim 18 , loperamide HCl claim 18 , manoalide (Ca release inhibitor) claim 18 , nicardipine HCl (L-type) claim 18 , nifedipine (L-type) claim 18 , niguldipine HCl (L-type) claim 18 , nimodipine (L-type) claim 18 , nitrendipine (L-type) claim 18 , pimozide (L- and T-type) claim 18 , ruthenium red claim 18 , ryanodine (SR channels) claim 18 , taicatoxin claim ...

BLOOD SEPARATION AND CONCENTRATION SYSTEM

This invention provides an apparatus and methods to consistently separate and concentrate selected blood components. The system includes, e.g., a computerized fluid handling system to transfer blood components between a centrifugal blood separation disc, containers and a concentrator. 1. A disposable set comprising a separation disc , a concentrator and a second conduit , wherein the second conduit provides a fluid connection between the separation disc and the concentrator.2. The disposable set of claim 1 , further comprising a first conduit and one or more cassettes claim 1 , which cassettes comprise the first conduit and/or the second conduit claim 1 , which cassettes guidedly mount to system components claim 1 , thereby providing operative mounting of the disposable set to the system components.3. The disposable set of claim 2 , wherein the system components comprise one or more valves claim 2 , one or more detectors claim 2 , and/or more pumps.4. The disposable set of claim 2 , wherein the disposable set is manufactured from plastic.5. The disposable set of claim 2 , wherein the disposable set is sterilized by gamma radiation.6. The disposable set of claim 6 , further comprising a sealed container which encloses the disposable set.759-. (canceled)60. The concentrated blood components of claim 88 , wherein the concentrated blood components comprise one or more growth factors present at a level 2-fold or more over peripheral blood levels.61. The concentrated blood components of claim 60 , wherein the growth factors are selected from the list consisting of EGF claim 60 , IGF claim 60 , PDGF claim 60 , TGF claim 60 , VEGF and FGF.62. The concentrated blood components of claim 60 , wherein the growth factor is EGF at a concentration of more than 100 pg per ml.63. The concentrated blood components of claim 60 , wherein the growth factor is FGF at a concentration of more than 150 pg per ml.64. The concentrated blood components of claim 60 , wherein the growth factor ...

SPERM CRYOPROTECTIVE MEDIA

Described herein are methods for sperm cryoprotection and compositions comprising a cryoprotectant; a membrane protectant that stabilizes or assists in stabilization of membranes of sperm; and a free radical scavenger (e.g., a reducing agent, an antioxidant). 1. A method for cryogenically preserving rodent sperm , comprising adding to the sperm , prior to cryopreservation , a composition that comprises at least one cryoprotectant; at least one membrane protectant; and reduced glutathione , beta-mercaptoethanol or a combination thereof.2. The method of claim 1 , wherein the cryoprotectant is selected from the group consisting of raffinose claim 1 , lactose claim 1 , trehalose claim 1 , melibiose claim 1 , melezitose claim 1 , mannotriose claim 1 , stachyose claim 1 , dextran claim 1 , sucrose claim 1 , and sugar alcohols thereof claim 1 , glycerol claim 1 , maltitol claim 1 , and lactitol.3. The method of claim 1 , wherein the cryoprotectant is raffinose or lactose.4. The method of claim 1 , wherein the membrane protectant is a protein selected from the group consisting of egg protein claim 1 , egg yolk protein claim 1 , egg white protein claim 1 , casein claim 1 , albumin claim 1 , keratin claim 1 , collagen claim 1 , atelocollagen claim 1 , elastin claim 1 , gelatin claim 1 , peptones claim 1 , fibrinogen claim 1 , fibronectin claim 1 , a soy protein claim 1 , a wheat protein claim 1 , a corn protein claim 1 , a milk protein claim 1 , and hydrolysates thereof.5. The method of claim 1 , wherein the membrane protectant is skim milk or a component thereof milk powder or a component thereof; or egg yolk or a component thereof.6. The method of claim 1 , wherein the rodent sperm is isolated from a mouse.7. The method of claim 6 , wherein the mouse is an inbred mouse strain or substrain.8. The method of claim 1 , wherein the rodent sperm is isolated from a rat.9. The method of claim 1 , wherein the cryoprotectant is raffinose claim 1 , lactose claim 1 , or glycerol; the ...

Method for Improving Vein Performance in Bypass Surgery

Methods to reduce damage to organelles, cells, tissues, organs and organ systems or components thereof caused by strain due to mechanical stress, including stretch stress and shear stress, are provided. The methods involve treating the organelles, cells, tissues, organs, and organs systems or components thereof (such as veins used for grafts in bypass surgery) with PX-18 and related compounds. Treatment with PX-18 and related compounds reduces damage due to stress and improves the functioning of the cells, tissues, organs or organs systems or components thereof. For example, the methods prevent the buildup of atherosclerotic plaque in transplanted (grafted) veins after coronary bypass surgery.

PERFUSION SOLUTION

The invention provides a perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na; a source of 10 to 20 mM K; a source of 5 to 10 mM Mg; a source of 0.25 to 0.75 mM Ca; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,/N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N/-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO; 1 to 30 mM glucose; 1 to 20 U/L insulin; 1 to 10 mM fructose diphosphate or a salt thereof; 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and optionally a diluent. The invention also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition. 1. A perfusion stock composition , for preserving a donor organ for transplantation , comprising:{'sup': '+', '(a) a source of 60 to 100 mM Na;'}{'sup': '+', '(b) a source of 10 to 20 mM K;'}{'sup': '2+', '(c) a source of 5 to 10 mM Mg;'}{'sup': '2+', '(d) a source of 0.25 to 0.75 mM Ca;'}(e) 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES);{'sub': '3', 'sup': '−', '(f) a source of 10 to 30 mM HCO;'}(g) 1 to 30 mM glucose;(h) 1 to 20 U/L insulin;(i) 1 to 10 mM fructose diphosphate or a salt thereof;(j) 1 to 40 mM aspartate or glutamate;(k) 1 to 10 mM adenosine, cAMP or cGMP;(l) 1 to 10 mM reduced glutathione; and(m) 30 to 100 mM lactobionate or mannitol; and optionally(n) a ...

METHODS AND SYSTEMS FOR PROCESSING BIOLOGICAL FLUIDS

Methods and container systems for processing biological fluids are disclosed. The container systems include an inner container within an outer container. The inner container wall is made of a porous material of a selected porosity that allows certain components to pass through said porous wall but retains other components. A treating solution is introduced into the chamber of the outer container. 1. A container system for the treatment of a biological fluid comprising:a) an outer container including an interior chamber;b) an inner container suspended within said interior chamber of said outer container, said inner container comprising at least one wall defining an interior chamber of said inner container, wherein said wall is made of a porous material selected to allow passage of only certain components of said biological fluid across said wall;c) a port communicating with said interior chamber of said outer container; andd) at least one port communicating with said inner container.2. The container system of wherein said inner and outer containers are made a flexible polymeric material.3. The container system of wherein at least said outer container is made of rigid polymeric material.4. The container system of wherein said outer container includes a sealed peripheral edge and said inner container includes a peripheral edge captured within said outer container peripheral sealed edge.5. The container system of wherein said inner container is suspended within said interior chamber of said outer container.6. The container system of comprising a flow path that communicates with at least said one port and said inner chamber of said inner container.7. The container system of Claim wherein said inner container has a surface area of approximately 150-400 cmand said outer container has a surface area of approximately 250-600 cm.8. The container system of further comprising a sample pouch in flow communication with one of said interior chamber of said inner container and said ...

ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS

The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. 111-. (canceled)12. A method for cryopreserving an in vitro cell population comprising:a. obtaining cells to be cryopreserved;b. incubating the cells to be cryopreserved in a freezing medium comprising dimethyl sulfoxide solution (DMSO) for longer than 5 minutes; andc. decreasing the temperature of the cells to be cryopreserved to less than 0° C. following incubation in DMSO.13. The method of wherein the cells to be cryopreserved are human pancreatic progenitor cells.14. The method of wherein the cells to be cryopreserved are human pancreatic progenitor cell aggregates.15. The method of wherein the freezing medium further comprises compounds selected from the group comprising Dulbecco's Modified Eagle's Medium (DMEM) claim 12 , Xeno-free Knockout Serum Replacement claim 12 , (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid) (HEPES) and combinations thereof.16. The method of wherein the freezing medium further comprises DMEM with 30% Xeno-free Knockout Serum Replacement claim 14 , 25 mM HEPES and 10% DMSO solution.17. The method of wherein the cells to be cryopreserved are incubated in the freezing media for about 60 minutes.18. The method of wherein the cells to be cryopreserved are incubated in the freezing media for about 15 minutes at ambient temperature and then 45 minutes at 4° C.19. The method of claim 12 , wherein the cells to be cryopreserved are loaded into an implantable semi-permeable device prior to step b.20. The method of wherein the temperature of the cells to be cryopreserved in step c is decreased to at least −20° C.21. The method of wherein the temperature of the cells to be cryopreserved in step c is decreased to at least −90° C.22. The method of wherein the temperature of the cells to be ...

SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS

Disclosed are devices for collecting and stabilizing blood or plasma and which contain an anti-coagulant, an antiplatelet agent, and a solubilization agent, and which may optionally include at least one other blood stabilization agent. Methods of making and using the devices in clinical medicine are also provided. 1. A device for collecting and stabilizing blood or plasma , comprising a first end and a second end and at least one interior wall defining a reservoir portion for receiving whole blood or plasma , and which comprises an anticoagulant , an antiplatelet agent comprising a prostaglandin , a phosphodiesterase inhibitor , a cyclooxygenase inhibitor , or a combination or two or more thereof , and a solubilization agent , wherein the anticoagulant and the antiplatelet agent are each present in an amount to stabilize the blood or plasma.2. The device of claim 1 , wherein the anticoagulant is selected from the group consisting of EDTA or a salt thereof claim 1 , oxalates claim 1 , citrate claim 1 , heparin claim 1 , a combination of citrate claim 1 , theophylline claim 1 , adenosine and dipyridamole (CTAD) claim 1 , sodium polyanethol sulfonate claim 1 , acid citrate dextrose claim 1 , and combinations of two or more thereof.3. The device of claim 1 , wherein the anticoagulant is present in a concentration of about 1 mM to about 200 mM claim 1 , relative to volume of the blood or plasma collected into the device.4. The device of claim 1 , wherein the antiplatelet agent is a prostaglandin.5. The device of claim 4 , wherein the prostaglandin comprises prostaglandin E1 claim 4 , prostaglandin E2 or a combination thereof.6. The device of claim 1 , wherein the prostacyclin comprises carbaprostacyclin claim 1 , beraprost claim 1 , iloprost claim 1 , 5 claim 1 ,6-dihydroprostacyclin claim 1 , ciprostene claim 1 , limaprost claim 1 , 13 claim 1 ,14-dehydro-15-cyclohexyl carbaprostacyclin claim 1 , taprostene claim 1 , and or a combination of two or more thereof.7. The ...

Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures

Compositions and methods are disclosed for substantially liquid, gel, suspension, slurry, semisolid and/or colloid storage of biological samples following admixture with the herein disclosed storage composition, permitting substantial recovery of biological activity following storage without refrigeration. In certain embodiments, unfractionated saliva samples may be stored without refrigeration for weeks, months or years in a form that permits recovery of intact DNA following the storage period.

Method for dental pulp cryopreservation

The present invention relates to a method for cryopreserving the pulp of a non-exfoliated deciduous tooth, comprising a step of making with a laser a hole into the tooth removed from its physiological seat on the tooth neck. After making the hole, the tooth is contacted with a cryopreserving agent and then cryofrozen. An object of the invention further consists in mesenchymal stem cells isolated from the pulp of a cryopreserved tooth according to the method of the invention.

CRITICAL POINT DRYING SYSTEMS AND METHODS FOR IN SITU TISSUE PRESERVATION

Methods and systems for preserving tissues in situ using critical point drying are disclosed. Such methods and systems are particularly applicable to the preservation of a deceased body, such as a deceased person or animal, with or without removal of internal tissues or organs. A fixative can be perfused through the vascular system of the body while blood is removed from the body. The exterior of the body can also be immersed in a bath of fixative. The fixative in the vascular system and the bath can be replaced by subsequent washes of buffer, de-ionized water, and/or alcohol. The alcohol-infused and fixated body can be disposed in a pressure chamber and subjected to a critical point drying process using carbon dioxide. After the critical point drying process, the body is in a preserved state. 1. A method for preserving a deceased body or an organ thereof , the method comprising:perfusing the body or the organ with fixative delivered via the vascular system thereof, and, at a same time as the perfusing with fixative, exposing external surfaces of the body or the organ to fixative;after the perfusing with fixative, perfusing the body or the organ with liquid carbon dioxide delivered via the vascular system thereof;after the perfusing with liquid carbon dioxide, heating the body or the organ in a sealed chamber until the temperature and pressure in said chamber meet or exceed the critical point for carbon dioxide2. The method of claim 1 , further comprising claim 1 , after the heating claim 1 , exhausting the carbon dioxide from the body.3. The method of claim 1 , further comprising claim 1 , before the perfusing with liquid carbon dioxide and after the perfusing with fixative claim 1 , perfusing the body or the organ with deionized water delivered via the vascular system thereof.4. The method of claim 3 , further comprising claim 3 , after the perfusing with deionized water and before the perfusing with liquid carbon dioxide claim 3 , perfusing the body or the organ ...

METHODS FOR PROCESSING SPERM CELLS

A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles. 180-. (canceled)81. A method of cryopreserving sperm cells comprising the steps of:adding a cryoprotectant to a quantity of sperm cells;cooling said quantity of sperm cells and said cryoprotectant to a holding temperature in a range of about 0-8° C.;maintaining said sperm cells and said cryoprotectant substantially at said holding temperature for a period of less than 60 minutes; andsupercooling said quantity of sperm cells to a temperature of −40° C.82. The method of claim 81 , wherein said holding temperature is in a range of about 2-6° C.83. The method of claim 81 , wherein said holding temperature is in a range of about 4-5° C.84. The method of claim 81 , wherein the cooling step comprises cooling said quantity of sperm at a substantially constant cooling rate.85. The method of claim 84 , wherein the cooling rate is selected so that said quantity of sperm cells is cooled from a temperature above a glass transition temperature below which sperm cells are subject damage from cold shock to the holding temperature in about 90 minutes.86. ...

Sperm processing methods

A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles.

PORTABLE DEVICE FOR EX VIVO STIMULATION OF WHOLE BLOOD

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood. 1. A system for the ex vivo stimulation of blood during transport of the blood comprising:a portable device adapted to generate and maintain at least two temperature ranges within the device comprising: 'wherein said cavity is dimensioned to contain a plurality of blood collection tubes;', 'an insulated device shell having an internal cavity,'} wherein said heating source is adapted to maintain the temperature within the device shell at a first temperature in a range between about 25° C. and 40° C. for a first period of time,', 'wherein said first period of time is at least one hour after activation of the heating source,', 'wherein said heating source is adapted to be inactivated after said first period of time has elapsed, and wherein the temperature fluctuation around said maintained temperature is within ±2.5° C.; and, 'a heating source positioned within said internal cavity,'} wherein said cooling source is adapted to be simultaneously active with said heating source during said first period of time, and', {'b': '4', 'wherein said cooling source is capable of maintaining adapted to maintain the temperature within the device at a second temperature which is below room temperature for a second period of time of at least hours after said first period of time has elapsed with a temperature fluctuation around said second temperature of within ±5° C.'}], 'a cooling source,'}2. The system of claim 1 , wherein said first temperature phase comprises a maintained temperature of about 37° C.±2.5° C. and wherein said second temperature phase comprises a maintained temperature of about 4° C.±5° C.3. (canceled)4. The system of claim 1 , further comprising a plurality of blood collection tubes claim 1 , said blood collection tubes ...

Spray Dried Human Plasma

The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma power, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. 1. A method for spray drying plasma , the method comprising:providing plasma to a spray drying apparatus;spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder; andstoring the physiologically active plasma powder.239-. (canceled)40. A product comprising:a physiologically active dried plasma in the form of a powder.4161-. (canceled)62. An apparatus for spray drying plasma comprising:a plasma source;a pressurized spray gas source;a drying gas source;a spray dry nozzle in sterile fluid communication with the plasma and spray gas sources;a drying chamber in sterile fluid communication with the spray dry nozzle and the drying gas source to receive a spray of plasma from the nozzle for drying;a particle collection device configured to collect spray dried plasma from an outlet of the drying chamber; anda collection device gas outlet port in fluid communication with the collection device, the gas outlet port comprising a sterile outlet port;wherein the spray nozzle, drying chamber, and collection device define a sterile isolated interior volume.6372-. (canceled)73. An attachment for a plasma spray drying apparatus comprising:a plasma inlet port for sterile attachment to a plasma source;a spray gas inlet port for removable sterile attachment to a pressurized gas source;at least one drying gas inlet port for removable sterile attachment to a drying gas source;a spray dry nozzle in fluid communication with the plasma and spray gas inlets;a drying chamber in fluid communication with the attached spray nozzle and drying gas inlet to receive a spray of plasma for drying;a ...

Tissue retrieval, storage, and explant culture device for the derivation of stem cells

A device is provided for securing a tissue sample from biological material. The tissue sample is housed in bottom and top platens that are configured to promote fluid communication between the tissue sample and the exterior environment to permit transport or cryogenic fluid to contact the sample. Additionally, diskette assemblies may be provided within the platens that permit sub-samples to be separated without directly handling the tissue sample. The diskette assemblies may also be configured to promote fluid communication with the sub-sample housed therein.

Cryoembedded cell concentrates, methods for making, and methods for using

Methods for preparing a cryoembedded cell concentrate are disclosed. The cryoembedded cell concentrate can be sectioned for use in methods (e.g., immunohistochemistry assays, immunocytochemistry assays, methods that use light or fluorescent microscopy, in situ hybridization assays, or diagnostic methods). Also disclosed are kits comprising cryoembedded cell concentrates.

HEPARAIN-BULKING AGENT COMPOSITIONS AND METHODS THEREOF

A free-flowing anti-coagulant powder composition, the anti-coagulant composition containing heparin and a bulking agent that is lyophilized or spray dried and ground into a powder. The powdered anti-coagulant composition can be dry filled into syringes and other blood collections systems for rapid dissolution and mixing with collected blood sample without agitation of the container. The formulation may also retain a portion of the initial moisture, which may improve the shelf life and stability of the composition. 1. A method of preparing a heparin-bulking agent composition , the method comprising:providing a heparin component and at least one bulking agent;dissolving the heparin component and the at least one bulking agent in a solution to form a heparin-bulking agent formulation;drying the heparin-bulking agent formulation to form a heparin-bulking agent composition having a solid mass; andgrinding the solid mass of the heparin-bulking agent composition to a particulate size such that the heparin-bulking agent composition comprises a free-flowing powder.2. The method of claim 1 , wherein the heparin component is a heparin salt chosen from lithium claim 1 , sodium claim 1 , calcium claim 1 , zinc or combinations thereof.3. The method of claim 2 , wherein the heparin component is provided as a solution claim 2 , an aqueous solution claim 2 , a solid material claim 2 , or a lyophilized heparin salt.4. The method of claim 2 , wherein the bulking agent is a water soluble material chosen from a sugar alcohol claim 2 , a carbohydrate claim 2 , a water-soluble polymer claim 2 , or combinations thereof.5. The method of claim 4 , wherein the water soluble material is chosen from mannitol claim 4 , trehalose claim 4 , raffinose claim 4 , sorbitol claim 4 , sucrose claim 4 , lactose claim 4 , polyvinylpyrollidone claim 4 , and combinations thereof.6. The method of claim 5 , wherein the water soluble bulking agent is provided as an aqueous solution or a solid material.7. The ...

MICROFLUIDIC DEVICE AND METHOD FOR MODULATING A GAS ENVIRONMENT OF CELL CULTURES AND TISSUES

A microfluidic device having a perfusion chamber, the perfusion chamber having a base, a bath opening in the base, a supply inlet and an exhaust outlet. The device further includes a gas permeable membrane attached beneath the perfusion chamber, the gas permeable membrane having a first opening in registration with the supply inlet and a second opening in registration with the exhaust outlet. A substrate is attached to the gas permeable membrane, the substrate having at least one microchannel arranged for flow communication with the supply inlet and the exhaust outlet. In addition, a slide is attached to the substrate. As such, gas introduced through the supply inlet is communicated to the microchannel via the first opening, and the gas permeable membrane is positioned to be exposed to the gas to communicate the gas to the bath opening. 1. An microfluidic device comprising:a perfusion chamber, the perfusion chamber having a base, a bath opening in the base, a supply inlet, and an exhaust outlet;a gas permeable membrane attached beneath the perfusion chamber, the gas permeable membrane having a first opening in registration with the supply inlet and a second opening in registration with the exhaust outlet;a substrate attached to the gas permeable membrane, the substrate having at least one microchannel arranged for flow communication with the supply inlet and the exhaust outlet; anda slide attached to the substrate;wherein a gas introduced through the supply inlet is communicated to the microchannel via the first opening, and further wherein the gas permeable membrane is positioned to be exposed to the gas to communicate the gas to the bath opening.2. The microfluidic device of claim 1 , wherein the bath opening defines an area to receive biological material claim 1 , the biological material comprising one or more of a brain slice or cultured cells.3. The microfluidic device of claim 1 , wherein a top surface of the gas permeable membrane defines an area to receive ...

COMPOSITIONS, METHODS AND DEVICES FOR MAINTAINING AN ORGAN

Compositions, methods, systems/devices and media are provided for maintaining a harvested organ in a functioning and viable state prior to implantation. The organ perfusion apparatus includes a preservation chamber for storing the organ during the preservation period. A perfusion circuit is provided having a first line for providing an oxygenated fluid to the organ, and a second line for carrying depleted fluid away from the organ. The perfusion apparatus also includes a device operably associated with the perfusion circuit for maintaining the organ at a substantially normothermic temperature. 1. A method for perfusing a heart , comprisingplacing the heart in an ex-vivo apparatus,perfusing the heart with a fluid to cause the heart function in a viable state, andmaintaining the heart at a physiologic temperature during perfusion.2. The method of claim 1 , including controlling perfusion pressure.3. The method of claim 1 , including therapeutically treating the heart.4. The method of claim 1 , including controlling flow rate of the perfusion fluid.5. The method of claim 1 , including oxygenating the fluid.6. The method of claim 1 , including pumping the fluid in pulsatile fashion.7. The method of claim 1 , including transporting the heart from a first location to a second location remote from the first location.8. The method of claim 1 , including diagnosing a condition of the heart.9. The method of claim 1 , including maintaining the heart for more than about 6 hours.10. The method of claim 1 , including maintaining the heart for more than about 24 hours.11. A method for evaluating a heart for a transplant claim 1 , comprisingplacing the heart in an ex-vivo apparatus,perfusing the heart to cause it to function in a viable state,maintaining the heart at a physiologic temperature during perfusion, andperforming one or more tests on the heart during perfusion.12. The method of claim 11 , including performing an echocardiogram on the heart during perfusion.13. The method ...

ORGAN PROTECTION, PRESERVATION AND RECOVERY

This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ. 1. A method for reducing damage to a cell , tissue or organ following ischemia comprising:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.2. A method according to claim 1 , wherein the composition further includes a delta-1-opioid receptor agonist.3. A method according to claim 2 , wherein the opioid is [D-Pen 2 claim 2 ,5]enkaphalin (DPDPE).4. A method according to claim 1 , wherein the adenosine receptor agonist is CCPA.5. A method for reducing damage to a cell claim 1 , tissue or organ following trauma comprising:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.6. A method for reducing damage to a cell claim 1 , tissue or organ during ischemia or reperfusion:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.7. A method for reducing damage to a cell claim 1 , tissue or organ following ischemia comprising administering to the cell claim 1 , tissue or organ an effective amount of a composition including (i) a potassium channel opener or ...

Lid For Functionalized Microfluidic Platform And Method

A microfluidic device and method is provided for handheld diagnostics and assays. A first substance is frozen in a cryopreservation fluid in a first well of a lid. The lid includes a first surface communicating with a first port of the first well and a second surface communicating with a second port of the first well. A porous membrane is affixed to the first surface so as to overlap the first port and a non-porous membrane is affixed to the second surface so as to overlap the second port. The first substance may be dialytically freed from the cryopreservation fluid at a user desired time. Thereafter, the lid may be moved from a first position wherein the lid is spaced from a base to a second position wherein the lid is adjacent the channel in the base such that the first substance communicates with the input of the channel.

Cooling system, especially for cryopreserving biological samples, comprising devices for use in case of an emergency

A cooling system ( 1 ), especially for cryopreserving biological samples ( 2 ), comprises a cooling chamber ( 100 ) delimited by a bottom area ( 110 ), side walls ( 120 ), and a top area ( 130 ), and a cooling device ( 200 ) for cooling the cooling chamber ( 100 ) using liquid nitrogen ( 220 ). At least one of the side walls ( 120 ) includes at least one predetermined wall element ( 125 ) which is a portion of at least one of the side walls and can be moved relative to the associated side wall ( 120 ) in such a way that a wall opening can be formed in said side wall ( 120 ). Methods for operating the cooling system ( 1 ) in case of an emergency are also described.

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals. 1199-. (canceled)200. An improved method of producing an embryo using ART by reducing stress on the sperm cell during sperm processing , comprising:a. forming a sperm cell composition by adding one or more OSRs in the concentration range of 0.01 to 5 mg/ml to the sperm cell sample,b. holding the sperm cell composition for a period of time,c. processing the sperm cell composition, andd. using the sperm cell composition in assisted reproductive techniques (ART).201. The method of producing an embryo according to the method of claim 200 , wherein the ART is selected from the group consisting of: in vitro fertilization (IVF) claim 200 , artificial insemination (AI) claim 200 , intracytoplasmic sperm injection (ICSI) claim 200 , multiple ovulation and embryo transfer (MOET) claim 200 , and other embryo transfer techniques.202. The method of producing an embryo according to the method of claim 200 , wherein two or more OSRs are added at multiple processing steps to further enhance the integrity of the sperm and the embryo made with the ...

Fluid for Suspended Animation

A method to increase the time a donated organ will remain viable prior to transplantation, where the method includes infusing into a human patient declared brain dead, using a first intravenous line, a fluorocarbon fluid comprising a chain length from 1 to about 20 carbon atoms, and optionally synchronously with said infusing, exsanguinating said patient using a second intravenous line. 1. A method to increase the time one or more donated organs will remain viable prior to transplantation , comprising:after a decision is made to terminate life-support for a human patient declared brain dead, infusing using a first intravenous line said patient with a fluorocarbon fluid comprising a chain length from 1 to about 20 carbon atoms; andharvesting said one or more organs.2. The method of claim 1 , further comprising synchronously with said infusing claim 1 , exsanguinating said patient using a second intravenous line.3. The method of claim 2 , further comprising synchronously with said infusing and said exsanguinating claim 2 , ventilating said patient with oxygen.4. The method of claim 1 , further comprising nebulizing said fluorocarbon fluid with 100 percent oxygen prior to said infusing.5. The method of claim 1 , wherein said fluorocarbon fluid comprises dodecafluoropentane.6. The method of claim 1 , further comprising:prior to said infusing, forming a composition comprising said fluorocarbon fluid in combination with an aqueous solution comprising sodium ions, potassium ions, calcium ions and magnesium ions.7. The method of claim 6 , wherein said aqueous solution further comprises chloride ions and bicarbonate ions.8. The method of claim 6 , wherein said aqueous solution further comprises one or more saccharides.9. The method of claim 6 , wherein said aqueous solution further comprises one or more amino acids or salts thereof.10. The method of claim 6 , wherein said aqueous solution further comprises one or more vitamins.11. The method of claim 6 , wherein said aqueous ...

Cell-permeable variants of trehalose and methods for the protection of living cells

A method for synthesizing variants of Tre; novel Tre variants; and a method for introducing Tre in sufficient concentration into the intracellular environment suitable to store treated mammalian cells, treat an aggregation disease, and protect treated cells from oxygen radicals are disclosed.

ARRESTING OBJECTS

A method and system for arresting objects in an array of chambers including, applying a solution to at least one chamber in an array of chambers, in a manner that does not connect two chambers, such that at least one object in the solution is arrested in said at least one chamber, the chambers having a volume of 0.5 microliters-3 microliters. 1. A method of arresting objects in an array of chambers comprising:applying a solution to at least one chamber in an array of chambers, in a manner that isolates said at least one chamber, such that at least one object in said solution is arrested in said at least one chamber; andsubstantially sealing said at least one chamber against escape of said objects by a liquid or a film or a gel cover for said at least one chamber, or by a plug.2. A method as in claim 1 , wherein said solution is applied to two chambers claim 1 , then said at least one chamber is isolated by reducing an amount of said solution in and/or around said chambers.3. A method as in claim 1 , wherein said solution is applied to said at least one chamber to a level no more than a height of walls of said at least one chamber.4. (canceled)5. A method as in claim 1 , wherein said cover comprises a fluid floating above said solution.6. A method as in claim 1 , wherein said cover repels water from said chambers.7. A method as in claim 1 , wherein said cover is a liquid claim 1 , and further comprising inserting said solution including said at least one object into said at least one chamber through said cover.89-. (canceled)10. A method as in claim 2 , wherein the amount of said solution is reduced by wicking.11. A method as in claim 1 , wherein said at least one object comprises a living cell or a molecule.12. A method as in claim 1 , wherein said at least one object comprises a sperm cell or a DNA molecule.1314-. (canceled)15. A method as in claim 1 , further including cryopreserving said arrested objects in said chambers.16. (canceled)17. A system according to ...

Method for Preserving Cells and Cell Cultures

Provided is a method for reducing apoptosis in nucleated cells. The method entails holding nucleated cells in a container and adding a gas containing xenon to the container so that the pressure inside the container reaches between 0.5 to 4.0 Atm above ambient pressure; holding the container at between 0.5 to 4.0 Atm above ambient pressure for a period of time during which the temperature in the container is between 22° C. and 37° C.; lowering the temperature in the container to between 0.1° C. and 10° C. while maintaining the pressure of 0.5 to 4.0 Atm above ambient pressure and holding the container for a period of time; and reducing the pressure in the container to ambient pressure and increasing the temperature to 22° C.-37° C. By performing these steps, the cells undergo less apoptosis than a reference.

METHOD OF FREEZING CELLS

The invention discloses a multi-layer cell freezing vial and method of ohtention thereof. The method of obtention is a cell freezing and thawing process that avoids the need of incorporating new fresh medium to the thawed cells for the dilution of the cryoprotective agent. This is achieved by the previous freezing of an extra layer of culture medium in addition to the frozen ceil solution containing said cryoprotective agent. At the time of thawing, the culture medium and the cell solution mix themselves, turning the concentration of said cryoprotective agent to a non-toxic dilution and achieving the effective exclusion of said cryoprotective agent from the living cells. 2. A method according to claim 1 , wherein the volume of said cells or cell-like materials or non-human embryos solution layer is equal or less than half the volume of said liquid diluent layer.3. A method according to claim 1 , comprising the steps of:a) adding, onto the frozen cells or cell-like materials or non-human embryos solution on top of the double-layer frozen body, a layer of hypoxic biologically acceptable liquid diluent; andb) freezing the result of the previous step to obtain a triple-layer frozen body.4. A method according to claim 3 , wherein said hypoxic biologically acceptable liquid diluent is an anoxic biologically acceptable liquid diluent.5. A method according to claim 1 , wherein said biologically acceptable liquid diluent is complete cell culture medium.6. A method according to claim 5 , wherein said complete cell culture medium is supplemented with at least one antibiotic and/or serum.7. A method according to claim 1 , wherein said cryogenic agent is selected among the group of DMSO claim 1 , glycerol claim 1 , polyvinyl-pyrrolidone claim 1 , ethylene glycol claim 1 , methanol claim 1 , methyl acetamide and sugars.8. A method according to claim 1 , wherein said cells are microorganisms.9. A method according to claim 1 , wherein said cells are plant cells.10. A method ...

APPARATUS FOR MAINTAINING A HARVESTED ORGAN VIABLE AND TRANSPORTABLE

An apparatus for enclosing an organ after harvesting and before implantation, having; a vessel enclosing a fluid, a connection tube for connecting a circulation hose to the organ for passing a fluid to the organ by a pump, and a degassing hose extending from the connection tube to the vessel. A pinch valve is arranged in the degassing hose. During a degassing phase, the pinch valve is opened to allow fluid flow from the pump, via the circulation hose to the connection tube and via the degassing hose to the vessel for expelling air entrapped in the fluid flow system. A balloon is arranged to prevent fluid flow via the connection tube to the organ during the degassing phase. A sterility arrangement closes the vessel at the top and may be replaced by further sterility arrangements without compromising the sterility. 1. An apparatus for enclosing an organ after harvesting and before implantation , comprising:a vessel enclosing a fluid;a connection tube for connecting a circulation hose to the organ for passing a fluid to the organ by means of a pump;a degassing hose extending from the connection tube from a position adjacent the connection of the connection tube with an inlet part of the organ and to said vessel; anda valve member arranged in said degassing hose for preventing fluid flow therein;whereby during a degassing phase, the valve member is opened to allow fluid flow from the pump, via said circulation hose to said connection tube and via said degassing hose to said vessel for expelling air entrapped in said fluid flow system.2. The apparatus according to claim 1 , wherein said connection tube comprises an occlusion member arranged to prevent fluid flow via said connection tube to said organ during said degassing phase.3. The apparatus according to claim 2 , wherein said occlusion member is a balloon member which is connected to a pump via a balloon hose for expansion of the balloon member by means of said pump in order to obstruct fluid flow via the connection ...

GAS-FILLED MICROBUBBLES AND SYSTEMS FOR GAS DELIVERY

Compressible and concentrated suspensions containing gas-filled microbubbles, uses thereof for delivering gas into a subject in need thereof, and systems for delivering the compressible suspensions. The gas-filled microbubbles each comprise a gas core surrounded by a lipid membrane, which includes (a) one or more lipids, such as 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC) or dipalmitoylphosphatidylcholine (DPPC), and (b) one or more stabilizing detergents, such as poloxamer 188, Pluronic F108, Pluronic F127, polyoxyethylene (100) stearyl ether, cholesterol, gelatin, polyvinylpyrrolidone (PVP), and sodium deoxycholate (NaDoc). 1. A gas-filled microbubble , comprising a lipid membrane encapsulating a gas core , wherein the lipid membrane contains (a) 1 ,2-disteroyl-sn-glycero-3-phosphocholine (DSPC) or dipalmitoylphosphatidylcholine (DPPC) , and (b) one or more stabilizing detergents selected from the group consisting of poloxamer 188 , a poloxamer having a molecular weight lower than that of poloxamer 188 , Pluronic F108 , Pluronic F127 , polyoxyethylene (100) stearyl ether , cholesterol , gelatin , polyvinylpyrrolidone (PVP) , and sodium deoxycholate (NaDoc).2. The gas-filled microbubble of claim 1 , wherein the one or more stabilizing detergents are poloxamer 188 claim 1 , polyoxyethylene (100) stearyl ether claim 1 , cholesterol claim 1 , Pluronic F108 claim 1 , and PVP.3. The gas-filled microbubble of claim 1 , wherein the microbubble has a diameter of 1 to 10 microns.4. (canceled)5. The gas-filled microbubble of claim 1 , wherein the gas core consists of oxygen claim 1 , carbon dioxide claim 1 , carbon monoxide claim 1 , nitric oxide claim 1 , inhalational anesthetic claim 1 , hydrogen sulfide claim 1 , or a mixture thereof.6. (canceled)7. The gas-filled microbubble of claim 1 , wherein the lipid membrane contains:DSPC and poloxamer 188;DSPC and polyoxyethylene (100) stearyl ether;DSPC and cholesterol;DSPC, poloxamer 188, and PVP, orDSPC, Pluronic F108, PVP ...

Organ arrest, protection, preservation and recovery

The present invention relates to a composition for controlling viability of a tissue including a potassium channel opener or adenosine receptor agonist, a compound for inducing local anaesthesia and compound for reducing the uptake of water by a cell in the tissue. The present invention also relates to the use of the composition according to the invention for controlling viability of a tissue.

Method and apparatus for prevention of thermo-mechanical fracturing in vitrified tissue using rapid cooling and warming by persufflation

A method and apparatus are disclosed for avoiding fracturing, e.g., thermo-mechanical fracturing, in vitrified biological systems via rapid cooling and/or warming persufflation techniques, by reducing the domain size of fracturing and by reducing thermal gradients. Also disclosed is a system adapted to rapidly cool and warm vitrifiable vascular biological tissue by persufflation, significantly reducing cryoprotectant toxicity from that of surface cooled tissue, in which the system is constructed and configured to use one or more of helium gas, hydrogen gas, neon gas, argon gas, krypton gas, xenon gas, oxygen gas, or various gaseous compounds. The system can be operated under pressure to increase the density and heat capacity of the gas relative to its density and heat capacity at atmospheric pressure and to cool the gas by one or more of mechanical action and by the phase change of a material such as a cryogenic gas or solid.

ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2)

The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and of one or more of a potassium channel opener, an adenosine receptor agonist, an anti-adrenergic, a calcium antagonist, an opioid, an NO donor and a sodium hydrogen exchange inhibitor. 125-. (canceled)26. A method for reducing electrical disturbance of a cell's resting membrane potential comprising administering to the cell an effective amount of a composition comprising an effective amount of (i) a local anaesthetic; and (ii) at least one of a potassium channel opener , an adenosine receptor agonist , an anti-adrenergic , a calcium antagonist , an opioid , an NO donor and a sodium hydrogen exchange inhibitor , said composition further comprising a physiological potassium concentration.27. A method for reducing damage to a cell , tissue or organ following ischaemia comprising administering to the cell , tissue or organ an effective amount of a composition comprising an effective amount of (i) a local anesthetic; and (ii) at least one of a potassium channel opener , an adenosine receptor agonist , an anti-adrenergic , a calcium antagonist , an opioid , an NO donor and a sodium hydrogen exchange inhibitor , said composition further comprising a physiological potassium concentration.28. A method for preconditioning a cell or tissue during ischaemia or reperfusion comprising administering an effective amount of a composition comprising an effective amount of (i) a local anesthetic; and (ii) at least one of a potassium channel opener , an adenosine receptor agonist , an anti-adrenergic , a calcium antagonist , an opioid , an NO donor and a sodium hydrogen exchange inhibitor , said composition further comprising a physiological potassium concentration.29. A method for reducing damage to a cell , organ or tissue before , during and following ...

ORGAN TRANSPORT APPARATUS WITH SAMPLE COMPARTMENTS

An apparatus for at least one of storage, treatment, assessment and transport of an organ or tissue includes a coolant container configured to cool the organ or tissue, a perfusion circuit configured to perfuse the organ or tissue, and a sample compartment for holding a biological sample. Preferred apparatus has a first internal compartment under a first cover (lid) of the apparatus that includes the coolant container and the sample compartment. The apparatus can include a second internal compartment under a second cover (lid) of the apparatus, the second internal compartment including at least part of the perfusion circuit and a sample compartment. 1. An apparatus for at least one of storage , treatment , assessment and transport of an organ or tissue , the apparatus comprising:a coolant container having a cooling surface configured to cool the organ or tissue; anda first sample compartment for holding a biological sample separate from the organ or tissue, whereinthe coolant container is configured to cool the first sample compartment.2. The apparatus of claim 1 , wherein the coolant container defines a wall of the first sample compartment.3. The apparatus of claim 1 , whereinthe coolant container has a first cavity and a second cavity,the first cavity is configured to cool and support the organ or tissue, andthe second cavity is configured to cool and support the biological sample.4. The apparatus of claim 3 , wherein the first cavity and the second cavity are separate from each other.5. The apparatus of claim 3 , wherein the second cavity defines at least a wall of the first sample compartment.6. The apparatus of claim 3 , wherein the second cavity is located at a corner of the coolant container.7. The apparatus of claim 1 , further comprising: the cooling surface of the coolant container; and', 'the first sample compartment; and, 'a first internal compartment under a first cover of the apparatus, the first internal compartment includinga second internal ...

Perfusion apparatus with reduced pressure fluctuations, and bubble trap

An apparatus for separating gas bubbles that may be entrained in perfusate flow prevents such bubbles from continuing downstream and entering an organ or tissue. The apparatus may include a chamber having a top wall, a bottom wall and side walls. The chamber may include an inlet configured to allow at least one of gas and liquid to enter the chamber, an air opening configured to allow at least gas to exit the chamber and a first liquid opening configured to allow at least liquid to exit the chamber. The apparatus may function as an accumulator that reduces or eliminates pulsatility of the liquid flow and pressure. The apparatus may include a minimum volume of gas, initially or through the accumulation of gas, such that flow and pressure fluctuations in the liquid are dampened or eliminated. The apparatus may include a sampling port in a wall of the chamber.

Cannula

A cannula includes a first clamping surface on a closing portion of the cannula, a second clamping surface on a base of a cannula, a connecting structure that connects the closing portion and the base. The connecting structure may allow the closing portion to be rotated around the second clamping surface. The cannula may include a repeatably removable handle.

Organ transporter with tilt and/or shock sensing

An apparatus for perfusing an organ or tissue includes a perfusion circuit configured to perfuse the organ or tissue; at least one shock and/or tilt detector such as an accelerometer; and a controller. The controller may be configured to control perfusion based upon a signal received from the accelerometer, which may include stopping and/or starting the perfusion based upon the signal. The controller may also or alternatively sense and/or record shocks experienced by the apparatus.

Organ transporter with oxygen generation

An apparatus for perfusing an organ or tissue includes a perfusion circuit for perfusing the organ or tissue; an oxygenator for oxygenating perfusate that circulates through the perfusion circuit; and an oxygen supply device such as an oxygen concentrator or an oxygen generator configured to supply oxygen to the oxygenator. A method of perfusing an organ or tissue includes producing oxygen from a device such as an oxygen concentrator and an oxygen generator; supplying the produced oxygen, preferably as the oxygen is produced, to a perfusate to oxygenate the perfusate; and perfusing the organ or tissue with the oxygenated perfusate. The produced oxygen preferably has a concentration greater than the oxygen concentration in air.

System for collecting and preserving tissue cores

A thermal system for preserving tissue is disclosed. The cooling system comprises a base member, a temperature control sleeve constructed of a thermally conductive material, and a selectively removable lid member. The base member defines a reservoir and receives the temperature control sleeve. The temperature control sleeve at least partially defines a tissue collector chamber that is configured to receive a tissue collector. The temperature control sleeve is in communication with the reservoir. The reservoir is configured to receive a cooling medium. A slit formed within the tissue collection chamber that is sized to receive a tubing connected to the tissue collector therethrough. The lid member is configured to be selectively attached to the base member, and permit access to a tube mount for the tissue collector when the lid is attached to the base member.

Methods for Collecting and Processing Autografts, Processed Autografts, Kits for Collecting and Transporting Autografts, and Tools for Preparing Autografts

The present invention is directed to methods for collecting and processing autografts, processed autografts, kits for collecting and transporting autografts, and tools for preparing autografts. It is also directed to autologous bone grafts, and methods of preparing them. 1. A method of making a clean , disinfected autologous tissue implant , the method comprisinga) receiving a treated tissue that has been removed from a patient,b) processing the treated tissue to clean and disinfect the tissue, andc) providing the stored tissue to a surgical facility for re-implantation of the clean, disinfected tissue into the patient.2. The method of claim 1 , wherein the tissue comprises bone claim 1 , tendon or ligament.3. The method of claim 2 , wherein the tissue is a cranial bone flap.4. The method of claim 1 , wherein the received claim 1 , treated tissue was treated with an antibiotic solution claim 1 , a bactericidal solution claim 1 , a virucidal claim 1 , a glycerol-containing solution claim 1 , water claim 1 , saline or a combination thereof.5. The method of claim 1 , wherein the processing comprises at least one cleaning step.6. The method of claim 2 , wherein the processing comprises debridement.7. The method of claim 1 , wherein the processing comprises subjecting the tissue to a plasticizer.8. The method of claim 2 , wherein the processing comprises creating an instrument insertion site in the tissue.9. The method of claim 2 , wherein the processing comprises demineralization of the bone.10. The method of claim 1 , wherein the processing comprises exposing the tissue to at least one bioactive factor.11. The method of claim 1 , wherein the tissue is irradiated after processing.12. The method of claim 1 , further comprising storing the processed tissue in a storage solution.13. The method claim 12 , wherein the tissue is irradiated while in the storage solution.14. The method of claim 1 , further comprising seeding cells onto the tissue prior to re-implantation.15. A ...

Method for Preparing Adipose Tissue

This disclosure presents methodologies for processing, cryogenic storage, retrieval and preparation of a tissue for transplantation. As such, the methods provide a system by which tissue for transplantation can be reliably and safely processed and stored for an extended period of time until the tissue is desired to be used. 1. A method for maintaining viability of a tissue for transplantation , comprising removing a tissue sample from a subject , adding cryoprotectant to the sample , freezing the sample , and storing the sample in liquid nitrogen.2. The method of claim 1 , wherein said tissue is adipose tissue.3. The method of claim 1 , wherein the cryoprotectant is sterile phosphate buffered saline solution (PBS) containing 3-6% (v/v) human serum albumin (HSA) and 10% (v/v) dimethyl sulfoxide (DMSO).4. The method of claim 1 , wherein the sample is placed in a cryostorage container prior to freezing the sample.5. The method of claim 4 , wherein the cryostorage container is a cryobag.6. The method of claim 1 , wherein the sample is frozen to −140° C.7. The method of claim 6 , wherein the freezing process comprises:i. cooling the sample to −5° C. at a rate of −1° C. per minute;ii. cooling the sample to −50° C. at a rate of −25° C. per minute;iii. heating the sample to −12° C. at a rate of +15° C. per minute;iv. cooling the sample to −40° C. at a rate of −1° C. per minute; andv. cooling the sample to −140° C. at a rate of −10° C. per minute.8. The method of claim 1 , further comprising removing the sample from storage claim 1 , thawing the sample claim 1 , removing the cryoprotectant from the sample claim 1 , and preparing the sample for transplantation into a subject.9. The method of claim 8 , wherein the sample is thawed in a 38° C. water bath claim 8 , and the sample is kept at 2°-6° C. subsequent to thawing.10. The method of claim 8 , wherein after the cryoprotectant is removed claim 8 , the sample is washed with saline and maintained in a buffered physiologic ...

METHODS AND COMPOSITIONS FOR PRESERVING TISSUES AND ORGANS

The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage. 198-. (canceled)100. The method of claim 99 , wherein determining a measure of viability comprises comparing a measured energy parameter to a threshold representative of a transplantability threshold of an organ and/or a threshold representative of a cell harvesting threshold of an organ.101. The method of claim 99 , further comprising storing the organ prior to assessing its viability.102. The method of claim 99 , further comprising implanting the organ in a subject.103. The method of claim 99 , further comprising harvesting the cells of the organ.104. The method of claim 99 , wherein measuring for at least one energy parameter comprises assaying for the level of ATP in the organ claim 99 , measuring cellular energy status claim 99 , measuring the cellular energy status during normothermic perfusion of the organ claim 99 , measuring the level of a plurality of metabolites claim 99 , measuring the oxygen consumption by the organ claim 99 , measuring the level of the gluconeogenesis of the ...

Cooling apparatus used for cryonic preservation, and corresponding operating method

The invention relates to a cooling apparatus, especially for cryogenically preserving biological samples, including a duct ( 5 ) for delivering a coolant ( 3 ) to a cooling chamber ( 1 ), a heater ( 6 ) that has an adjustable first heating performance (P 2 ) for heating the coolant ( 3 ) delivered to the cooling chamber ( 1 ), a first temperature sensor ( 8 - 10 ) for measuring the temperature (T 2 -T 4 ) in the cooling chamber ( 1 ), a second temperature sensor ( 7 ) for measuring the temperature (Ti) of the coolant ( 3 ) delivered to the cooling chamber (I), and a regulator ( 11 ) for regulating the temperature. The regulator ( 11 ) is embodied as a multiple regulator which detects several temperatures (T 1 -T 4 ) as control variables and/or adjusts several heating performances (P 1, P 2 ) as manipulated variables. The invention further relates to a corresponding operating method.

METHOD OF CRYOPRESERVATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIAL CELLS ON POLYMERIC SUBSTRATE

Disclosed herein are methods and compositions for the cryopreservation of stem cells, such as stem-cell derived retinal pigment epithelial cells, that have been seeded onto and cultured on a substrate, such as a polymeric substrate. Such cryopreserved stem cells are useful for cell therapies, such as treatment of ocular damage or disease. 1. A method of cryopreserving stem cells on a substrate , the method comprising:exposing a substrate seeded with stem cells to a temperature ramp-down phase temperature reduction rate of from about 10° C. per 10 seconds to about 10° C. per 120 seconds,wherein the substrate comprises parylene,wherein the substrate has one or more characteristics that enhance viability of the seeded stem cells;transferring the cell-seeded substrate to a temperature between about 0° C. to about −100° C. for a first period of time; andmaintaining the stem cells at a storage temperature for a second period of time, thereby obtaining cryopreserved stem cells.2. The method of claim 1 , wherein the substrate is exposed to said temperature ramp-down phase such that the stem cell-seeded substrate reaches a temperature of around 0° C.3. (canceled)4. The method of claim 1 , wherein said first period of time is about 24 hours.5. (canceled)6. The method of claim 1 , wherein said second period of time is greater than about 72 hours.7. (canceled)8. The method of claim 1 , wherein the substrate further comprises a coating to enhance adhesion of the stem cells to the substrate.9. The method of claim 8 , wherein the coating comprises one or more of Matrigel claim 8 , vitronectin claim 8 , and retronectin.10. The method of claim 9 , wherein said coating enhances the viability of the stem cells during cryopreservation claim 9 , after cryopreservation claim 9 , or both.11. The method of claim 1 , wherein said characteristics of the substrate comprise one or more of the coefficient of thermal expansion of the substrate claim 1 , a substrate elasticity parameter claim 1 , ...

Kit of ophthalmic composition

An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.

DEHYDRATION DEVICE AND METHODS FOR DRYING BIOLOGICAL MATERIALS

This invention relates generally to a dehydration device and methods for drying biological materials to produce dried biological materials having enhanced structural properties. More specifically, the invention relates to a dehydration device and related methods for drying biological tissue to produce enhanced tissue grafts. 1. A dehydration device for use in drying biological material , comprising:a drying housing defining a drying chamber and defining inflow and outflow apertures;an inflow plenum in communication with the inflow apertures;an outflow plenum in communication with the outflow apertures; andan air-moving assembly configured to deliver air to the inflow plenum and receive the return air from the outflow plenum;wherein in use the biological material is placed into the drying chamber to dehydrate the biological material.2. The dehydration device of claim 1 , wherein the inflow and outflow plenums are integrally formed with the drying housing and the inflow and outflow apertures are provided by arrays of uniformly arranged and aligned apertures.3. The dehydration device of claim 1 , further comprising an air-heating assembly configured to selectively heat the air delivered to the inflow plenum.4. The dehydration device of claim 1 , further comprising a control system configured to control the operating parameters of the device to dry the biological material.5. The dehydration device of claim 1 , wherein the drying chamber is maintained at a humidity of less than 10%.6. The dehydration device of claim 1 , wherein the air delivered by the air-moving assembly is an inert gas.7. The dehydration device of claim 1 , wherein two or more biological materials are placed into the drying chamber to be dehydrated at the same time.8. The dehydration device of claim 1 , wherein the biological material is placental tissue.9. A dehydration device for use in drying placental tissue claim 1 , comprising:a drying housing defining a drying chamber and defining inflow and ...

HEMATOLOGY CONTROL COMPOSITIONS WITH EXTENDED STABILITY

The present specification provides hematology control compositions having particular utility with a red blood cell component for devices using electronic and optical means for blood determinations, and methods for using the compositions. 114-. (canceled)15. A hematology control composition comprising a red blood cell component and an isotonic suspension medium including a serum albumin component and a cholesterol component , wherein the composition has a free fatty acid concentration of less than about 4 mmol/liter; and wherein the serum albumin component and the cholesterol component are present in amounts sufficient to provide a stable shelf life.16. The composition of claim 15 , wherein the serum albumin component and the cholesterol component are present in amounts sufficient to provide a shelf life of the composition of at least ninety-five days.17. The composition of claim 15 , wherein the shelf life of the composition is represented by a stabilization in mean cell volume claim 15 , a stabilization in red blood cell distribution width claim 15 , or both.18. The composition of claim 15 , wherein the red blood cell component is present in an amount sufficient to be measurable with an automated hematology instrument.19. The composition of claim 15 , wherein the serum albumin component is present at a concentration of from about 30 grams/liter to about 50 grams/liter.20. The composition of claim 15 , wherein the serum albumin component comprises a ratio of serum albumin monomer to serum albumin dimer lower than about 5:1.21. The composition of claim 15 , wherein the cholesterol component is present at a concentration of from about 400 mg/liter to about 1200 mg/liter.22. The composition of claim 15 , further comprising a nonionic surfactant component.23. The composition of claim 22 , wherein the nonionic surfactant component comprises a poloxamer.24. The composition of claim 15 , which further comprises a white blood cell component.25. The composition of claim 24 , ...

Stem cell packaging and shipping

This invention concerns methods of packaging and shipping stem cells. Also disclosed are related package products.

Stable Protein Storage and Stable Nucleic Acid Storage in Recoverable Form

The invention provides compositions and methods for storage of biomolecules. The biomolecules are stored via absorption to a substrate. Absorbed biomolecules can be eluted or recovered from the substrate at a future time, and optionally be subjected to a subsequent analysis or application. Biomolecules absorbed to a substrate for storage may also optionally be preserved, i.e., the absorbed biomolecule is resistant to or resists degradation. 15-. (canceled)6. A composition comprising a porous or semi-porous elastomeric substrate and a peptide or a nucleic acid absorbed to the elastomeric substrate , wherein:the elastomeric substrate is substantially free of moisture;the peptide or nucleic acid absorbed to the elastomeric substrate has higher resistance to degradation than a peptide or a nucleic acid not absorbed to the elastomeric substrate; andat least a portion of the absorbed peptide or nucleic acid is recoverable from the elastomeric substrate.7. The composition of claim 6 , wherein the elastomeric substrate comprising the peptide or nucleic acid absorbed thereto contains less than 25% water by mass relative to the total mass of the absorbed substrate.8. The composition of claim 6 , wherein the peptide or nucleic acid absorbed to the elastomeric substrate resists degradation for at least 5 weeks at ambient temperature.9. The composition of claim 6 , wherein at least 30% of the peptide or nucleic acid absorbed to the elastomeric substrate is recoverable from the substrate.10. The composition of claim 6 , wherein the peptide or nucleic acid is isolated or purified peptide or nucleic acid.11. The composition of claim 6 , wherein the peptide or nucleic acid is part of a biological sample.12. The composition of claim 11 , wherein the biological sample comprises cells claim 11 , a tissue claim 11 , biopsied cells or tissue claim 11 , skin cells claim 11 , a tumor claim 11 , blood claim 11 , serum claim 11 , plasma claim 11 , saliva claim 11 , sputum claim 11 , mucus ...

EMULSIONS OF PERFLUOROCARBONS

The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process for preparing a pharmaceutical product containing a PFC emulsion and a process for validating a batch of an emulsion for pharmaceutical use. 121-. (canceled)22. A method of manufacturing a perfluorocarbon emulsion comprising the steps:a) mixing an emulsifier and aqueous medium together;b) adding perfluorocarbon to the mixture of step a);c) mixing the mixture of step b) to form a coarse emulsion;d) obtaining a sample of the coarse emulsion of step c) and determining particle size distribution of the sample;e) if the sample of step d) has a monomodal particle size distribution, then homogenizing the coarse emulsion of step c); andf) obtaining the emulsion.23. The method of claim 22 , wherein in step e) the coarse emulsion of step c) is homogenized only if the median particle size of the sample of step d) is less than 20 μm.24. The method of claim 22 , wherein in step e) the coarse emulsion is homogenized at or above 7 claim 22 ,000 psi.25. A process for preparing a pharmaceutical product containing a PFC emulsion claim 22 , the process comprising:a) obtaining a batch of perfluorocarbon emulsion or coarse emulsion; 2) determining the total amount of residual fluoride present in the batch; or', '3) determining the total amount of lysophosphatidylcholine (LPTC) present in the batch; and, 'b)1) determining the particle size distribution of the batch;'}c) preparing the pharmaceutical product from the batch only if 1) the batch is determined to have a monomodal particle size distribution; 2) the batch is determined to have less than 40 ppm residual fluoride by weight of the emulsion; or 3) the batch is determined to have less ...

Graft or tissue rinsing solution and method for rinsing said graft or tissue before revascularization

Extracellular organ or tissue rinsing solution, comprising calcium, PEG with a molecular weight of 35 000 at a concentration of at least 4 g/l, and potassium at a concentration of greater than or equal to 1, but less than 10 mmol/l.